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ABSTRACT 
The memory T cell compartment comprises a plethora of subsets that are diverse at the 
functional, transcriptional and metabolic level. T memory stem cells (TSCM) are the least 
differentiated subset endowed with superior immune reconstitution capacity, anti-tumor 
activity and long-term persistence compared to more differentiated progeny in preclinical 
models. However, their role in human T cell recovery remains undetermined.  
In the first part of my work, I investigate the dynamics of T cell reconstitution in human 
haploidentical bone marrow transplantation (haplo-BMT) with post-transplant 
cyclophosphamide (pt-Cy) and provide evidence that donor antigen-specific naïve (TN)-
derived TSCM cells survive pt-Cy and are the most abundant circulating T cell population in 
the early days after transplantation. I further demonstrate that these cells later contribute to 
peripheral reconstitution by differentiating into effector cells. With these experiments, I 
define the cellular basis of human T cell reconstitution following haploidentical 
transplantation with pt-Cy and propose to employ naive-derived TSCM cells in the clinical 
setting to overcome immunodeficiency. However, the clinical use of these cells is limited by 
their paucity ex vivo. Therefore, I dedicate the second part of this work to investigate the 
biological and molecular mechanisms involved in the generation and expansion of TSCM cells 
from CD8+ TN precursors. I show that curtailed T-cell receptor stimulation curbs effector 
CD8+ T-cell differentiation and allows the generation of CD45RO–
CD45RA+CCR7+CD27+CD95+ -phenotype cells from highly purified TN precursors, 
resembling naturally-occurring TSCM. These cells proliferate extensively in vitro and in vivo, 
express low amounts of effector-associated genes and transcription factors and undergo 
considerable self-renewal in response to IL-15 while retaining effector differentiation 
potential. Such a phenotype is associated with a lower number of mitochondria compared to 
highly-activated effector T cells committed to terminal differentiation. These results shed 
light on the molecular signals that are required to generate high numbers of long-lived 
memory T cells with potential application in adoptive cell transfer immunotherapy. 
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1 INTRODUCTION 
1.1 Adaptive Immunity: maturation, differentiation and 
homeostasis of T cells 
T cells belong to the adaptive arm of the immune system. They derive from 
committed lymphoid progenitors cells that arise the bone marrow (BM) and infiltrate 
the thymus via the blood1. These progenitors, or thymocytes, maturate and generate 
both αβ and γδ T cells2. The maturation consists in the re-arrangement of variable 
(V), diversity (D) and joining (J ) segments of the T cell receptor (TCR) loci3. αβ 
double negative (DN) T cells first express a pre-non-rearranged TCR-α chain which 
pairs later with the TCR-β rearranged chain (pre-TCR-αβ)1. At the cell surface, the 
pre-TCR-αβ is associated with the intracellular CD3/ζ-complex-which is involved in 
the intracellular transduction of the signal4. The first active signal provided by 
cortical epithelial cells induces biochemical changes in the cytoplasmic portions of 
CD3 complex which includes the phosphorylation of the tyrosine-based activation 
motifs (ITAMs) by the Src family tyrosine kinase LCK and FYN1. These signals are 
fundamental for the selection of correct β-chain and further maturation of T cells2. 
This first active signal induces the proliferation of thymocytes, the rearrangement of 
α-chain and the generation of a fully mature TCR-αβ2. At these stage almost the 
90% of thymocytes are double positive (DP) for CD4 and CD8 costimulatory 
proteins2. DP cells are located in the cortex region of the thymus where they interact 
with self-peptides presented by major histocompatibility complex (MHC). The 
interaction with “self” is essential for thymocytes survival and for the commitment of 
DP cells towards CD4+ or CD8+ single positive (SP) T cell lineage (called positive 
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selection). The commitment towards the CD4+ or CD8+ T cell lineage depends on 
the interaction with two different classes of MHC expressed by cortical antigen 
presenting cells (APCs): MHC class I (MHC-I) induces the maturation of CD8+ T 
cells while MHC-II induces the maturation of CD4+ T cells5. T cells capable to 
survive positive selection migrate into the cortico-medullary junction of the thymus. 
Here, they encounter APCs such as macrophages, dendritic cells, bone-marrow 
derived APCs expressing tissue-restricted peptides:MHC. T cells which bind MHC 
with high affinity are harmful as they could lead to unwanted self-directed activities, 
thus are negative selected and die by apoptosis6. Those cells that have avoided 
negative selection maturate into naïve T cells (TN)6. Mature TN cells leave the 
thymus and reach secondary lymphoid organs (i.e. spleen and lymphnodes) where 
they continuously scan APCs in search of their cognate-antigen (Ag). After Ag 
recognition, TN cells undergo activation and generate more differentiated effector 
cells (expansion phase) whose function is to eliminate the pathogen or cancer 
cells1. After infection, the vast majority of T cells (95%) dies (contraction phase), 
while a small fraction survives and generates memory cells, which persist in the long 
term7. Memory cells are clonally expanded and activate more rapidly than TN cells, 
thus ensuring protection in case of re-infection8. 
1.1.1 Models of T cell memory formation 
After the resolution of primary infection, around 90-95% of CD8+ effector T cells 
die, while a small fraction survives and generates memory T cells with long-term 
persistence. The mechanisms that regulate T cell fate after activation remain poorly 
defined. In this regard, two main models of differentiation have been proposed. This 
first model, also called the “linear model”, proposes that memory cells are generated 
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from effector cells during the contraction phase after initial infection9. The second, 
alternative model is the “developmental model” according to which memory cells 
arise directly from TN cells that never experienced a full-activation and differentiation 
toward an effector stage9. The two models show different predictions about the 
proliferation capacity, self-renewal and multipotency of effector and memory 
subsets. The “linear model” predicts that memory cells have proliferated at least the 
same as effector cells from which they are generated9, although this is somehow 
confuted by the finding that the length of telomeres10,11,12 and activity of 
telomerase13 are both reduced in effector compared to memory cells9. Instead, 
these findings support the “developmental model” which predicts that memory cells 
proliferate less than effector cells during the acute phase. The predicted 
multipotency in the “linear model” is that effector cells are able to generate memory 
cells. On the other side, in the “developmental model” the effector cells are not 
expected to generate memory cells, as they are in a terminal developmental stage 
and are committed to die. In line with the “developmental model”, experiments of 
repeated Ag stimulation of T cells in vitro, showed an increased effector function but 
impaired memory formation14. Conversely, memory CD8+ T cells were able to 
generate more differentiated effector cells while generating a pool of cells 
maintaining their original phenotype15.  
In support to the “linear model”, Rafi Ahmed and colleagues recently showed that 
memory CD8+ T cells are generated from effector cells through a process of cellular 
de-differentiation. They investigated the epigenetic modifications (i.e. methylation 
associated with gene repression) of TN and effector-associated genes in terminal 
effectors (TE) and memory precursors (MP) during viral infection in vivo. The 
methylation profile of TN-associated genes and de-methylation of effector genes was 
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similar in MP and TE cells during infection. Longitudinal phenotypic and epigenetic 
analysis showed that at the end of infection, Ag-specific MP but not TE cells were 
able to de-methylate and re-express (both at the mRNA and protein level) TN 
associated genes, thus suggesting that MP cells generate memory through a 
mechanism of T cell de-differentiation16. 
With the improvement of single cell technologies (i.e. single cell adoptive transfer 
and tracking, single-cell quantitative PCR, RNA and DNA sequencing), researchers 
were recently able to provide a deep characterization of the CD8+ T comparment 
and its developmental potantial at the single cell level. Experiments based on the 
adoptive transfer of individually labeled T cells by the means of unique, inheritable 
DNA barcodes revealed the heterogeneity of TN response during infection9. In 
particular, Gerlach et al. tracked the progeny of individual mouse CD8+ TN cells and 
demonstrated that, even for T cells expressing the same TCR, both differentiation 
capacity and clonal expansion are heterogeneous. Specifically,  TN cells that 
experienced massive proliferation during the primary response preferentially 
generated KLRG-1+ effector cells, while those proliferating less preferentially 
differentiated into long-lived CD62L+CD27+ cells17. Similar findings were also 
confirmed by an independent group18. Using imaging techniques, Steven Reiner and 
colleagues reported that a TN cell undergoing its first cell division during Ag 
response segregates unequal amounts of molecules that are involved in fate 
specification, such as the IFN-g receptor, T-bet and others, to its daughter cells and 
subsequently demosntrated that the progeny has differential capacity to generate 
effector and memory cells19. All these findings are in support of the “developmental 
model” where differentiation and proliferation are tightly linked.  
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1.1.2 The complexity of the T cell memory compartment 
The T cell compartment is not merely composed by naïve and memory cells, but 
it is highly heterogeneous in terms of phenotypic composition, functional activity and 
capability to respond to homeostatic or antigenic stimulation20. Using monoclonal 
antibodies (mAbs) and flow cytometry, which allow the identification of lymphocytes 
at the single cell level, the heterogeneity of this compartment has been revealed21. 
In 1999, Sallusto and Lanzavecchia identified two subsets on the basis of different 
migratory capability in tissues and organs: the central memory (TCM) and the effector 
memory (TEM) T cells10. The latter preferentially migrate to peripheral tissues and 
show immediacy of effector functions in response to Ag re-exposure10. On the other 
hand, TCM migrate preferentially to secondary lymphoid organs, and show little 
immediate effector functions, although possess the capability to proliferate and 
differentiate rapidly upon Ag exposure10. Transitional memory cells (TTM) cells are 
more differentiated than TCM cells but not as fully differentiated as TEM cells in terms 
of phenotype and expansion capability in response to IL-15 in vivo22. The most 
differentiated memory subset is represented by the terminal effector cells (TTE)21. 
These cells, which are more frequent in the CD8+ than the CD4+ population, 
possess potent effector functions but are poorly proliferative and tend to die rapidly 
after activation, compared to less differentiated memory cells7,8,22.  
Almost 10 years ago, studies in mice and later in humans and rhesus macaque 
identified a new T cell subset, less differentiated than the TCM cells: the T stem cell 
memory, or TSCM cells15,23,24. This population represent 2-3% of total circulating 
peripheral blood mononuclear cells (PBMCs). Like TN cells, TSCM maintain the 
capability to self-renew, to generate more differentiated subsets, to undergo 
massive proliferation and to infiltrate secondary lymphoid organs15,23,24. On the other 
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hand, like memory cells, TSCM have undergone multiple cell divisions, as suggested 
by their lower content of T cell receptor excision circles (TREC, indicative of T cell 
divisions) compared to TN cells, proliferate in response to IL-15 and rapidly produce 
effector cytokines such as IFN-g, IL-2 and TNF-α after super-Ag stimulation15. 
Collectively, these data suggest that less differentiated T cells are able to generate 
more differentiated ones according to the relationship TN àTSCM à TCM à TTM à 
TEM à TTE , where less differentiated cells are endowed with superior multipotent, 
self-renewal, proliferative capacities and anti-tumor abilities24, while more 
differentiated cells preferentially infiltrate tissues and acquire rapidly cytotoxic and 
effector functions upon stimulation (Figure 1)15,22,24.  
1.1.3 Markers to define T cell subsets  
TN and memory subsets can be identified by the expression of a specific 
combination of surface and intracellular markers (Figure 1), as revealed by flow 
cytometry21,23,25,26.TN cells are characterized by the expression of different markers: 
the member of the tumor necrosis factor receptor CD27, the CC chemokine 
receptor-7 (CCR7) and the cell adhesion molecule L-selectin (CD62L), both 
necessary for the homing to secondary lymphoid organs, the long isoform of the 
tyrosine phosphatase CD45R (CD45RA), which is involved in T cell activation, the 
lymphocyte function-associated antigen-1 LFA-1 (CD11a) and LFA-3 (CD58)21,22. 
Moreover, TN cells express the α-chain of IL-7 Receptor (IL-7Rα or CD127), which 
has important implication for TN homeostasis by mediating their survival21,22.  
As regards the memory compartment, TSCM maintain a phenotype similar to TN 
cells (CCR7+, CD27+, CD45RA+, CD62L+, CD127+), however they upregulate the 
death receptor CD95 and the β-chain of the Interleukin (IL)-2/IL-15 receptor complex 
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(CD122), which are expressed by memory cells21. Similarly, TCM maintain the 
expression of naïve markers CD62L, CD127, CCR7 and CD27, but are CD45RA- 
while upregulate the CD45R shortest isoform, CD45RO8,20,22,27. Human TEM 
downregulate CCR7, are heterogeneous for CD62L and upregulate receptors 
necessary for the homing to inflamed tissues like CCR3, CCR5 and C-X-C Motif 
Chemokine Receptor-6 (CXCR6). CCR3, CCR5 and CXCR6 are largely expressed 
by TCM, TTM and TEM but not by TN and TSCM8,22,27. Like TCM, TEM retain the 
expression of CD45RO, CD95 and CD12221. TTE cells acquire CD45RA expression, 
however they are distinguished from TN cells by the absence of CCR7 and CD62L22. 
Moreover, TTE cells express exhaustion and senescence markers like the marker of 
terminal differentiation CD57, the killer cell lectin-like receptor -1 (KLRG-1) and 
display phosphorylation of histone H2AX (γH2AX), indicative of DNA damage8,27.  
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Figure 1. T cell differentiation process, functions and phenotype of T cells. Ploychromatic 
flow cytometry analysis allows the identification of T cells at the single cell level and permits the 
identification of different T cell subsets on the basis of specific combination of markers. In red, the 
markers that change during differentiation from the previous subsets. Going from less differentiated T 
cells to more differentiated ones, functional abilities also change. 
 
1.1.4 Homeostasis of human T cells 
The number of lymphocytes in the body is tightly controlled by homeostatic 
mechanisms that is the slowly turnover in the absence of Ag stimulation28,29. The 
maintenance of T cell numbers involves both common gamma chain (γc) cytokines 
(IL-2, IL-4, especially IL-7 and IL-15) and contact with self-pMHC expressed by 
APCs30. Sprent and coworkers established that under steady-state conditions, 
memory T cells turnover at a relatively higher rate compared to TN cells31,32. On the 
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other hand, homeostatic proliferation of  TN cells is more dependent on TCR-self 
pMHC interaction30. Indeed, they survive less than memory cells if deprived of TCR-
self pMHC contact33 34.  
An important role in homeostatic proliferation is held by common γc cytokines33-
35. Both TN and memory cells need common γc cytokines signals to undergo 
homeostatic proliferation34. It is now well known that TN cells are more dependent on 
IL-7 to self-renew compared to more differentiated cells34. IL-7 is produced in the 
bone marrow, thymus, secondary lymphoid tissues, liver and intestine by non-
hematopoietic stromal and epithelial cells36. The production of IL-7 is not dependent 
from external stimuli and is stable36. T cells respond to IL-7 via IL-7R36. This 
receptor is composed of 2 subunits: the common γ-chain CD132 (shared with IL-2, 
IL-4, IL-9, IL-15 receptors), and the α-chain (CD127), which confers cytokine 
specificity36. CD127 is expressed by all T cell subsets and is downregulated in TTE 
cells33. The essential role of IL-7 was discovered several years ago by the finding 
that blocking contact with IL-7, either by blocking IL-7R in normal mice or by 
adoptive transfer of T cells into IL-7 deficient mice, TN cells were not able to survive 
or to persist in the host36. At low levels,  IL-7 activates the downstream IL-7R 
pathway33. Binding of IL-7 to IL-7R induces the activation of Janus Kinase 1 (Jak1) 
and Janus Kinase 2 (Jak2), which are bound to CD127 and CD132, respectively36. 
This binding recruits the Signal Transducer and Activator of Transcription 5a/b 
(STAT5a/b), which migrates to the nucleus and upregulates the transcription of the 
antiapoptotic molecule Bcl-236. In lymphopenic conditions, the concentration of IL-7 
increases because of the reduced number of T cells34. The increased amount of IL-7 
amplifies the weak signal of TCR-self pMHC resulting in a gradual differentiation 
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towards memory cells37. However, the presence of memory cells reduces this 
mechanism, as they compete with TN cells for IL-7 signals30,32.  
Other cytokines are involved in T cell proliferation during lymphopenia, in 
particular IL-2 and IL-15. These cytokines are structurally and functionally related 
and share two of their receptor chains, the IL-2/15Rβ (CD122) and the common γc 
CD132. IL-15 is produced primarily by DCs, monocytes and epithelial cells in the 
presence of inflammatory signals38. Initially IL-15 was identified as a soluble 
molecule. Later it was shown that IL-15 also exists as a membrane-bound form 
complexed to the α-chain of its receptor (IL-15Rα) with high affinity. The membrane-
bound form, which is the prevalent form in vivo, binds target cells through the so-
called trans-presentation38. Trans-presentation is mediated by the membrane-bound 
complex IL-15/IL-15Rα. If non-complexed with IL-15Rα, IL-15 binds to IL-15Rβγ 
complex with lower affinity38, inducing activation of Src family molecules including 
Lymphocyte Cell-Specific Protein-Tyrosine Kinase (Lck) and Proto-oncogene 
Tyrosine-protein Kinase Fyn. These molecules subsequently induce 
Phosphoinositide 3-Kinase (PI3K) and Mitogen-Activated Protein Kinase (MAPK) 
signaling pathway39. 
Because IL-2 and IL-15 share receptor subunits (CD122, CD132), both these 
cytokines activate similar downstream pathways including activation of MAPK, the 
induction of Bcl-2, the phosphorylation of Lck and spleen tyrosine kinase (Syk)39. All 
these signals lead to maturation and proliferation of T cells39. IL-2Rα (CD25) and 
CD122 are progressively upregulated with T cell differentiation10,27 thus suggesting 
an important role of IL-15 in the homeostasis of memory, but not TN cells. The 
importance of IL-15 was demonstrated in studies where memory cells were 
transferred in IL-15 deficient mice. In these hosts, memory cells failed to undergo 
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homeostatic proliferation and died rapidly20. Similar results were obtained in mice 
deficient in one of three chains of IL-15R and IL-2R: IL-2Rα (CD25), IL-2Rβ 
(CD122) and IL-2Rγ (CD132)40,41. In these lymphopenic hosts donor TN cells 
proliferated and differentiated rapidly into memory and effector cells. Importantly, it 
was observed that IL-2 induced the generation of effector cells, while IL-15 
sustained memory differentiation40,41. To determine the role of γc-cytokines in T cell 
homeostasis, Geginat and coworkers investigated the acquisition of functional and 
phenotypic features of purified TN,TSCM, TCM, and TEM subsets isolated from human 
PBMCs20. Purified T cell subsets were activated in vitro via cytokine and antigenic 
stimulation. Cytokine stimulation was provided by IL-2, IL-7 and IL-15, while Ag 
activation was provided by mature DCs20. In the absence of antigenic stimulation, 
the response to IL-7 and IL-15 was low in all subsets, but proliferation increased 
when IL-2 was added to the cytokine cocktail20. Concerning the antigenic 
stimulation, the authors observed that TN activation was more dependent on 
costimulation compared to more differentiated T cells. Moreover, after T cell 
activation the capability to produce IFN-g increased over T cell differentiation, while 
less differentiated TN, TSCM and TCM cells produced mainly IL-210,20. Finally, they 
observed that all subsets generated CCR7-CD45RA- effector cells after Ag 
stimulation, while a fraction maintained the original phenotype. Similarly, TSCM cells 
were capable to generate more differentiated TCM and TEM upon TCR triggering, 
while 60% of them maintained the original phenotype. Conversely, only 30% of 
stimulated TCM were able to self-renew and they could only to differentiate into TEM 
subsets, thus indicating that at least in vitro, “de-differentiation” does not occur15. 
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1.1.5  Hematopoietic stem cell transplantation (HSCT) 
HSCT following either marrow-ablative or non-myeloablative condition regimen is 
widely used in the clinic for the treatment of multiple diseases, including lymphoma, 
acute and chronic leukemias, multiple myeloma, myelodysplastic syndromes, 
myeloproliferative disorders and autoimmune diseases.  Several clinical protocols 
have been developed over the years, and they differ in terms of:  
• stem cells source (e.g., bone marrow, umbilical cord blood, peripheral 
blood G-CSF mobilized stem cells); 
• type of transplant: autologous (transplanted cells derive from the 
patient), allogeneic (cells are isolated from a third-party donor), 
haploidentical (donor and patient share half of their HLA haplotype 
system) and HLA-identical; 
• type of conditioning regimen, classified on the basis of the duration of 
cytopenia: myeloablative conditioning (MA), causing irreversible 
cytopenia and in the need of stem cell (SC) support;  reduced-intensity 
conditioning (RIC), causing cytopenia for a variable duration and for 
which SC support is useful, and non myeloablative conditioning (NMA), 
causing minimal cytopenia and for which SC support is not necessary42;  
• depletion of T cells from donor graft in order to eliminate allo-reactive T 
cells. This approach is used to avoid the activation of donor T cells 
against recipient’s tissues that are recognized as non-self, a reaction 
collectively referred to as graft-versus-host-disease (GVHD), 
characterized by selective damage to the skin, liver, gastrointestinal 
tract and mucosa of patients43. The severity of GVHD is correlated to 
HLA mismatch between the donor and the recipient, and is defined as 
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acute (aGVHD) when observed in the first 100 days after BMT44, 
otherwise it is defined as chronic (cGVHD)45. Ex vivo T cell depletion, 
may be employed to prevent GVHD without the morbidity associated 
with immunosuppressive drugs46,47. This procedure reduces significantly 
the incidence and severity of GVHD, but does not improve overall 
survival. Moreover, donor T cells also play an important role in the 
prevention of infections and mediate malignancy eradication (graft-
versus-tumor effect)43. Thus, the absence of donor T cells in the graft is 
associated with increased risk of serious infections, relapse and death 
due to prolonged immune deficiency in the recipients43. For these 
reasons, other methods are required to selectively inhibit alloreactivity, 
while preserving immunity against pathogens and tumor cells. 
1.1.6 Unmanipulated HLA haplo-BMT with high dose cyclophosphamide 
Generally, the employment of HLA-identical relatives for allogeneic 
transplantation represent the best choice for HSCT or BMT. However, donor 
availability represents a major problem as only one-third of candidates for allogeneic 
BMT (allo-BMT) have HLA-matched donors45. To increase the number of potential 
donors for almost all patients, the group of Leo Luznik at the John’s Hopkins 
University in Baltimore, USA, developed an HLA-haploidentical BMT with high dose, 
post-transplant cyclophosphamide (Cy), given eraly after bone marrow infusion48-50. 
Cy, an alkylating agent employed since 1960s to modulate allograft responses51, 
selectively targets proliferating cells and induces apoptosis. In the contest of 
haploidentical transplantation, both donor and recipient cells proliferate quickly in 
response to allo-Ags, thus becoming susceptible to the effect of Cy51. Several 
24 
 
 
studies performed in mice showed that the administration of Cy early after allo 
transplantation prevents GVHD, thus increasing overall survival44. The 
administration of Cy early after transplant allows the elimination of allogeneic T 
cells, while non-allogeneic T cells are spared, respond to increased concentrations 
of homeostatic cytokines, mainly IL-2, IL-15 and IL-7, inflammatory cytokines 
(induced by pre-transplant conditioning) and exogenous Ags, thereby contributing to 
immune reconstitution48-50.  
1.1.7 T cell recovery after allogeneic stem cell transplantation 
Immunodeficiency after stem cell transplantation represents a crucial and 
inevitable condition for patients48. The chemotherapy, the intensity of transplant 
preparative regimen, the age of patients, the occurrence of aGVHD, the onset of 
CMV and opportunistic infections and the administration of immune-suppressive 
drugs all affect the recovery and function of T cells52. After transplantation, T cell 
numbers can be restored via two different pathways: peripheral expansion of 
residual oligoclonal T cells in response to Ags, allo-Ags or cytokines and generation 
of new TN cells from progenitors via thymopoiesis53. The former occurs early but can 
last up to 1 year after transplant due to the increased availability of cytokines 
(mainly IL-7 and IL-15), exogenous Ags or allo-Ags which induce the rapid 
expansion of the T cell pool52, while the latter occurs several months after 
transplantation and it is characterized by the generation of new TN cells. This 
“thymic dependent” pathway is capable to ideally restore a polyclonal T cell receptor 
repertoire52. The thymus is most productive in the first 6 months of life, but remains 
active during the first 20 years of life. In adults and in elderly the thymic output 
declines progressively, hence resulting in a reduction of T cell repertoire and 
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oligoclonal expansion of T cells52. For this reason, young individuals undergoing 
BMT are generally characterized by better T cell recovery compared to older 
individuals.  In this regard, multiple strategies have been conceived to independently 
improve the functionality of thymus, such as by altering the numbers of infused T 
progenitors, the intensity of conditioning regimen or administration of immune-
suppressive drugs 52. A clear understanding of the molecular mechanisms that 
govern the generation, the functionality and maintenance of T cells are therefore 
important to predict the immune-recovery after transplantation. 
1.2 Immunotherapy as alternative/additional approaches to HSCT 
and BMT 
Immunotherapy approaches based on vaccines, drugs or autologous T cell 
sources represent a powerful alternative for patients with large-state haematological 
malignancies, solid tumors and refractory diseases54. These approaches have 
several advantages compared to traditional therapies based on radiotherapy, 
chemotherapy and transplantation, as they are in general more specific for the 
cancer and, in the case of vaccines, have little or no side effects after immunization, 
high specificity and good safety profiles55. In this thesis, anti-cancer vaccines will not 
be discussed in detail. Despite a major effort of scientific research in the past two 
decades, induction of anti-tumor immunity by vaccination led to poor clinical results 
in terms of overall response and prolonged survival. The causes of such failure have 
to be ascribed to multiple reasons, including the difficulty in identifying cancer-
specific antigens and the poor immunogenicity of such antigens, among others. 
Below, I discuss a series of different immunotherapy approaches based on immune 
checkpoint inhibitors, tumor-specific neoantigens, adoptive cell transfer of ex vivo 
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expanded TILs, T cells expanded by Ag-pulsed APCs and T cells modified with Ags 
specific T cell receptors (TCR) or chimeric antigen receptors (CARs). These are 
only a minority of the enormous efforts made by scientists and clinicians to explore 
the complexity of cancer immunotherapy. 
1.2.1 Immune checkpoint inhibitors 
Humanized monoclonal antibodies (mAbs) directed to antigens expressed on 
tumor cells have now been employed in the clinic for nearly 20 years thanks to their 
potent anti-tumor effect. Initially, the use of mAbs was restricted to treat 
haematological malignancies, but recent developments on the so-called “immune 
checkpoint inhibitors” allow to treat solid tumors as well56. Immune checkpoints 
molecules are expressed on the surface of tumors or immune effector cells and their 
role is to counterbalance the positive effect of costimulation. Thus, these inhibitory 
molecules are required to achieve an appropriate immunological response57. In the 
absence of costimulation, activation of T cells is blunted and generates immune 
tolerance57. In this regard, immune checkpoint molecules limit effector responses, 
thus preventing harmful and unwanted self-directed activities58. Usually, tumor cells 
are capable to overexpress inhibitory molecules such as the cytotoxic T lymphocyte 
activation antigen 4 (CTLA-4) and the programmed death-1 (PD-1) receptor or 
ligand (PD-L1) which inhibit T cell activation and function55,59. Overcoming these 
mechanisms of peripheral tolerance by mAbs mediate tumor regression by 
unleashing anti-tumor immunity, that is mostly exerted by effector CD4+ and CD8+ T 
cells58. The anti-tumor activity of CTLA-4 inhibition have been investigated in 
numerous murine tumor models, such as renal cell carcinoma, prostate carcinoma 
and lymphoma60. In less immunogenic mice models such as mammary carcinoma 
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SM1 or melanoma B16, anti-CTLA-4 therapy did not demonstrate efficacy in tumor 
eradication. However, the combination of anti-CTLA-4 with other therapies such 
chemotherapy, radiation and a variety of vaccines with tumor antigens increased 
anti-tumor activity61. A similar study reported that treatment of metastatic melanoma 
patients with anti-CTLA4 mAb Ipilimumab improved overall survival, and 
demonstrated for the first time that the immune system can reject solid tumors62,61. 
Subsequent studies focused the attention on the PD-1/PD-L1 molecules, both 
overexpressed by tumor infiltrating T cells and tumor cells (e.g., breast, kidney, lung 
ovary, colon as well as non epithelial tumors such as melanoma, T cell lymphoma, 
multiple myeloma and various types of lymphomas)63. Mice tumor models of multiple 
myeloma, melanoma and mammary carcinoma showed that antibody-mediated 
blockade of PD-L1 promoted cancer regression60. Recent clinical trials using anti-
PD161 or anti- PD-L164,61 showed an enhanced T cell response in patients with late-
stage melanoma61. Anti-PD-1 is particularly effective in refractory or relapsed 
lymphomas65. However, despite reaching complete remission, patients are treated 
with allogeneic BMT to increase chances of cure. Immune checkpoint blockade is 
currently being tested in multiple cancer types. Despite significant clinical gains are 
observed in the setting of treatment with these molecules, the responses to this form 
of therapy are not effective in all cancer types, especially those with low mutational 
burden and/or low immunogenicity. In order to increase the anti-tumor activity of 
immune cells, additional tumor-specific molecules called neoantigens have been 
exploited. 
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1.2.2 Neoantigens 
In the last years a novel class of cancer-targets have been studied: the so called 
cancer neoantigens. These molecules represent a class of antigens derived from 
somatic DNA mutations (e.g. nonsynonymous point mutations, insertion-deletions, 
gene fusion and frameshift mutations) in cancer cells66. Thus, neoantigens are 
considered important targets for immunotherapy approaches because they are 
tumor-specific and lack of expression in normal tissues. Advances in next 
generation sequencing (NGS) technologies enabled the identifications of candidate 
neoantigens with relatively high accuracy . It is important to note, however, that the 
vast majority of mutations are not translated (i.e. nonsense mutations, non coding 
mutations)66. Instead, those mutated proteins that are translated must be processed 
into short peptide fragments and complexed with MHC-I/MHC-II molecules prior to 
the presentation on the cell-surface66. A number of computational tools have been 
developed in order to predict the structure, the binding affinity, the proteasomal 
processing and intracellular transportation of these hypothetical neoantigens66. 
Recent studies have demonstrated that approaches based on neoantigen vaccines 
are able to induce a robust anti-tumor activity in mice. Among these, Castel et al.67 
vaccinated the B16F10 melanoma mice with 50 different predicted neoantigens. 16 
of candidate neoantigens were immunogenic as assessed by IFN-g and ELISPOT-
assay, and 2 of them induced a marked anti-tumor activity in vivo. The identification 
of neoantigen-specific CD8+ and CD4+ T cells in TILs from melanoma patients and 
promising results from pre-clinical studies have induced a great interest in the 
generation of neoantigen-based vaccines. In a clinical trial performed by Ott et al., 
patients were vaccinated with neoantigens identified through NGS data from cancer 
and normal cells. The authors showed no disease recurrence in four of six 
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vaccinated melanoma patients at 20-30 month after surgical resection of the tumor. 
The remaining two patients achieved a complete remission after treatment with anti-
PD-1 antibody69. Similarly, Sahin et al. created a synthetic RNA-based vaccine 
encoding for neoantigens. Such RNA molecules were previously demonstrated to 
be taken up by DCs resident in lymph-nodes70. 8 of 13 vaccinated melanoma 
patients showed a complete tumor regression after vaccination during the entire 
follow-up period. The other 5 patients had cancer relapse. However, after anti-PD-1 
treatment, cancer regression was observed in one of these patients70. These works 
indicates that neoantigen-specific anti-tumor response occurs spontaneously in 
cancer patients and that neoantigens have the potential to be employed in vaccines 
to increase this pre-existing anti-tumor immunity. 
1.2.3 Adoptive cell transfer 
An alternative, effective immunotherapy approach based on the use of immune 
system to mediate tumor regression relies on adoptive T cell transfer (ACT), where 
anti-tumor T cells, either isolated from the patient or genetically-modified to confer 
tumor specificity, are activated and expanded in vitro (to increase their numbers) 
prior to infusion in the patient. The first ACT-based immunotherapy was used in the 
1980s, using lymphokine-activated killer (LAK) cells to treat tumors in mice models 
and humans71. Later, cytokine-induced killer (CIK) cells isolated and expanded from 
patient’s PBMCs were tested55. However, the low specificity of CIK and LAK-based 
therapies showed a limited efficacy55. Thus, more specific ACT-based methods 
were developed. One relies on the isolation, activation, expansion and re-infusion of 
tumor-infiltrating lymphocytes (TILs)55. The first TIL-based therapy was performed 
by Rosenberg et al. in 1988 for the treatment of melanoma patients72. In this trial, T 
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cells were isolated from patient’s tumor tissues, were expanded in vitro for two 
weeks using high-dose IL-2 (6000 U/mL) and then infused back into patients73. The 
treatment showed a significant objective response (cancer regression up to 29% of 
treated patients)73. However, the tumor regression was transient due to the low 
capability of T cells to persist in the host. More recently, clinical trials using a 
lymphodepleting preparative regimen followed by TIL infusion along with high-dose 
IL-2 showed an increase of anticancer responses (ranging from 49% to 72%) in 
melanoma patients55,74,75. It is thought that lymphodepletion eliminates 
immunosuppressive cells, in particular CD4+ regulatory T cells (Tregs) and myeloid-
derived suppressor cells (MDSCs) and autologous lymphocytes which compete for 
IL-7 and IL-15. The depletion of these cells results in the amplification of anti-tumor 
activity and persistence of infused TILs76. Despite the positive clinical outcome in 
melanoma patients, TIL-based therapies show some limitations. First, transferred T 
cells do not persist in the long term, thus limiting the anti-tumor effect. This is due to 
the initial quality of the isolated T cells, that are terminally-differentiated in origin. 
Moreover, IL-2, that is used for expansion, primes T cells for apoptosis. Second, 
TILs are generally specific for tumor-associated antigens that are also shared with 
normal cells, therefore ACT often results in autoimmune reactions77.  
Strategies are being developed in order to increase the persistence and the 
capability of T cells to specifically recognize and eliminate cancer cells. These 
methods include: T cells expanded by Ag-pulsed APCs and T cells modified with 
Ag-specific T cell receptors (TCR) or chimeric antigen receptors (CAR)55. In regard 
to the first method, T cells enriched from TILs or whole PBMCs are exposed to 
APCs previously pulsed with peptides derived from cancer cells, so that only tumor-
specific T cells are able to expand78,79. This method can ideally be employed in 
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nearly all patients as cancer-specific T cells can be obtained by stimulating 
autologous PBMCs. However, as mentioned above, the vast majority of such tumor 
Ags are generally self Ags expressed by normal cells, hence capable to trigger 
autoimmune reactions. Clinical trials using MelanA specific CD8 T cells showed 
tumor regression in 8 of 10 patients with refractory metastatic disease80. In a more 
recently clinical trial 11 patients with metastatic melanoma were treated with Cy as 
conditioning regimen, before the infusion of Ag-specific T cell additioned with low-
dose IL-2. This study showed that 5 of 11 patients had a stable disease, while 1 
patient had complete remission that lasted for 3 years after treatment81.  
The identification of tumor-specific peptides/epitopes has been a major effort of 
scientific research for decades, and has been recently exploited in the use of ACT 
where T cells are modified with antigen-specific TCRs or CARs. In this regard, 
autologous or third-party T cells are genetically modified in order to redirect T cells 
to recognize and eliminate cencer cells82. TCR-transduced T cells specific for Ags 
including cancer-testis antigen NY-ESO-1, Glycoprotein-100 (gp100), 
Carcinoembryonic antigen (CEA), Melanoma Antigen Recognized By T-Cells 1 
(MART-1) and Melanoma-Associated Antigen 3 (MAGEA3) have been tested in 
several clinical trials82. The first clinical trial using autologous T cells genetically 
modified to express the MART-1 TCR was reported by Rosenberg et al. in 2002 at 
the NIH83. In this study, melanoma patients showed cancer regression without 
autoimmune activity. Conversely, subsequently studies using MART-1-specific T 
cells with higher affinity for the Ag had little tumor regression and increased side 
effects such as autoimmune toxicity, as these cells mediated keratinocyte 
destruction. Immunotherapy approaches using engineered-TCR represent a 
promising strategy for anti-cancer therapy as anti-tumor activity is enhanced in the 
32 
 
 
presence of high affinity-TCR. However, clinical trials suggest that TCR with 
intermediate affinity are preferable, as high affinity T cells may induce severe 
autoimmunity disease.  
CARs are a valuable alternative to TCRs. CARs are hybrid receptors where the 
extracellular portion is a hybrid light chain immunoglobulin, bound to a spacer 
element, a transmembrane domain and an intracellular domain involved in T cell 
activation pathways73. CAR expression allows for redirection of T cell specificity 
towards a tumor-antigen independent of the MHC84. CARs are generally classified 
into three generations according to the number of signaling domains77. In the first-
generation, CARs contain the CD3x or the FC-g receptor domain. In the second and 
third generation, these receptors have additional costimulatory molecules such as 
CD28, CD27, Inducible T-Cell Costimulator (ICOS), 4-1BB (CD137), OX-40 
(CD134), which have been shown to improve T cell persistence, anti-tumor activity 
and proliferation, compared to first generation CARs54,77. Manufacturing of CAR T 
cells is a complex method involving multiple steps including: apheresis collection of 
T cells from peripheral blood of patient, T cell engineering via a CAR-expressing 
lentiviral or retroviral vector and expansion in vitro prior to infusion77. However, 
CARs have several advantages over TCRs. First, CARs are not MHC restricted, 
therefore they can be ideally employed in any patient. Second, tumor activity is not 
affected by tumor-escape mechanisms that are generally observed with the use of 
TCRs, such as HLA downregulation. Third, CARs could ideally target any protein, 
supposing antibodies against that protein have been generated77. The most 
promising results from CAR-based therapy was shown in patients affected by B cell 
malignancies treated with anti-CD19 CAR T cells in 200385-88. The authors showed 
that CD19 specific CAR T cells expanded and persisted following infusion, allowing 
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both tumor eradication and long-term surveillance85-88. CAR-T19 products were 
recently approved by the FDA in 2017 for the treatment of pediatric, young and adult 
relapsed/refractory B-cell ALL. Unfortunately, the vast majority of CAR-based 
therapies showed limited efficacy with serious side effects89. CAR-T cell based 
immunotherapy can result in unwanted toxicity in different ways. First, the infusion of 
large numbers of activated lymphocytes which recognize their target on tumor cells 
can induce the release of a high amount of pro-inflammatory cytokines (IL-6, IL-10, 
GM-CSF, TNF-a, IFN-g), thus generating a so-called “cytokine storm”90. This side 
effect can be controlled using steroids which in turn may limit the efficacy of CAR 
treatment91. Second, CARs can recognize molecules which are expressed by both 
normal and cancer cells, or they can cross-react with Ags expressed by normal 
cells. In both cases, CAR treatment can result in on-target off-tumor toxicity90.  
Despite different targets are currently being explored both at the preclinical and 
clinical level, CAR T cell therapy is still far from being used for the majorit of 
cancers. This is due to the lack of ideal cancer Ags, the short term persistence of T 
cells, the inefficient trafficking of T cells in tumor sites and presence of an 
immunosuppressive environment90. The limitations of CAR-based therapy are 
currently being studied. Recently, Yang et al. showed that the stimulation of Ag-
specific TCR expressed by CAR-T cells impairs the ability of CAR-CD8 (CAR8) to 
eliminate leukemic cells in vivo84. The  authors generated CAR-CD4 (CAR4) and 
CAR8 cells with defined endogenous TCR specificity for male minor 
histocompatibility antigen HY. They transferred HY-specific CAR4 and CAR8 cells 
from female donors into leukemic-bearing male (HY+) and female (HY-) mice and 
observed that despite HY-specific CAR4 T cells were able to eradicate tumor, when 
infused in both male and female mice, HY-specific CAR8 cells were not able to 
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eliminate leukemic cells, when infused in male mice. The simultaneous activation of 
TCR and CAR completely abolished the capacity of CAR8 cells to infiltrate the bone 
marrow. Moreover, these cells were more prone to apoptosis and showed an 
exhausted phenotype which is associated to a poor effectiveness of 
immunotherapy84. These observations shed light on the complex biological aspects 
of CAR T cell immune biology, indicating the necessity to rationally design CAR 
constructs in order to improve clinical efficacy. 
1.2.4 T cell differentiation status and ACT  
All the ACT based immunotherapies described previously show critical points 
which are poor expansion, low anti-tumor activity and low persistence of infused T 
cells due to the extended ex vivo manipulation. As described before, different T cell 
subsets are endowed with different capabilities to infiltrate inflamed tissues, to 
proliferate and to differentiate into potent effectors. In the scenario of a tumor, more 
differentiated CD62L–  memory T cells would be the preferred cells for ACT92. 
However, clinical data clearly indicate that the infusion of less differentiated cells 
correlates with a better clinical outcome. Several experiments were conducted in 
order to determine the correlation between differentiation status of T cells and anti-
tumor immune response92. In mice models of solid tumors it was demonstrated that 
TCM were expanded, persisted and eradicated tumors more efficiently than infused 
TEM93. According to these data, experiments conducted in immunodeficient mice and 
non-human primates showed that TEff originated from TCM persisted better than TEM-
derived TEff following ACT in vivo94,95.  
To date, the least differentiated memory T cells identified in humans, i.e. the TSCM 
mentioned in paragraph 1.1.1, are the preferred T cell subset to be used in ACT, 
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owing to their enhanced self-renewal and their capability to simultaneously derive 
potent, more differentiated effectors15,24,96. However, their paucity in the peripheral 
blood and at the tumor site limits their clinical use. For this reason, methods have 
been proposed to generate and expand the pool of existing TSCM from less 
differentiated naïve precursors15,23,37,97,98. 
1.2.5 Methods to generate TN-derived TSCM in vitro 
Immunotherapy approaches used in clinical trials largely employ TCR or CAR-
modified T cells derived from TILs or whole PBMCs. These methods simplify the 
manufacturing process that is, however, not standardized among patients as the 
PBMCs composition largely vary among individuals as a consequence of Ags 
exposure99, age 100 and systemic treatments101. Moreover, more differentiated 
subsets such as TEM and TTE , which are abundant in PBMCs (especially in the 
CD8+ population), are not able to generate viable T cell products in vitro102. Rather, 
they could inhibit the expansion and function of less differentiated T cells with 
enhanced capacity103.  
Effector and memory T cell differentiation is a complex process that involves the 
interaction of different molecules and pathways. Intense investigation over the past 
two decades led to the identification of the major molecular mechanisms that are 
involved in the generation of short-lived effectors and long-lived memory T cells. 
Memory T cell differentiation can be regulated at different levels, which in turn can 
result in the differential activation of signalling molecules, pathways and 
transcription factors (TFs). Schematically, 3 major levels of regulation can be 
identified: 
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• At the TCR signalling level, e.g., strength of the signal and type of 
costimulation; 
• At the intracellular level, e.g. TFs, signalling and metabolic pathways; 
• At the environmental (extracellular) level, e.g. cytokines, type of APC, 
presence of suppressive cell types, molecules, metabolites, etc. 
These regulatory checkpoints have been exploited in the recent years with the 
final aim to arrest T cell differentiation while promoting long-term memory 
development, an important correlation of functionality in ACT immunotherapy of 
cancer. I will not discuss the molecular mechanisms of memory T cell differentiation 
in detail, but will focus on those pathways whose manipulation has been show to 
induce TSCM cells. 
Following peptide recognition by the TCR, signal transduction is integrated at the 
level of PI3K/serine-threonine protein kinase (Akt) signalling pathway, which 
contributes to orchestrate downstream effector molecules and transcription factors 
such as Mammalian Target Of Rapamycin (mTOR), Nuclear Factor Kappa B (NF-
kB), JAK/ STAT and Forkhead Box O (FOXOs) transcription factor familiy. Since the 
amplitude of Akt stimulation correlates with effector cell formation, Kim et al. 
investigated the Akt blockade to increase CD8+ T cell memory formation104. 
Treatment of mice with pan-Akt inhibitor A-443654 reduced mTOR function during 
the expansion phase after infection and correlated with increased memory 
formation104. Along this line, human CD8+ T cell activation in the presence of Akt 
inhibitors allowed T cell proliferation while inhibiting differentiation, increased 
persistence following ACT in immunodeficient mice and improved anti-tumor 
responses in a xenogeneic model of myeloma105 and melanoma106.  
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Similarly, the Wnt/β-catenin signalling pathway has been shown to have a role in 
the generation and maintenance of CD8+ memory T cells107. In particular, studies 
involving constitutive expression or loss of function of β-catenin suggested that the 
survival and maintenance of memory CD8+ T cells are Wnt/β-catenin dependent. 
Studies by Restifo group showed that augmented Wnt signalling induced by 
glycogen synthase kinase-3β (GSK3β) inhibition favoured the generation of CD8+ 
TSCM from TN precursors both in mice54 and humans15 and showed increased anti-
tumor capability compared to memory T cells upon adoptive transfer. However, it is 
worth noting that GSK3b inhibition also impaired T cell expansion and decreased 
cell viability15,108. To improve the protocol, cytokines such as IL-7 and IL-21 were 
add to the stimulation cocktail. These cells expanded by ~6-fold and generated 
naturally-occurring TSCM97. In vitro generated human TSCM resulted 
transcriptomically, functionally and phenotypically similar to naturally occurring 
TSCM97. After activation, these cells were genetically modified to express a CD19-
CAR and were shown to possess potent anti-leukemic functions in immunodeficient 
mice97.  
Similarly, Cieri et al. stimulated CD62L+CD45RA+ TN cells with IL-7 and IL-15 
combined with strong aCD3/28 stimulation (3 beads:1 cell). The induced TSCM-like 
cells displayed a hybrid CD45RO+CD45RA+ phenotype that is rarely found in vivo37. 
Nevertheless, the cells expanded ~50-fold in vitro and persisted longer than TCM and 
TEM when infused in xenogeneic models compared to TCM and TEM37.  
Recently, it has been shown that epigenetic manipulation of T cell memory 
subsets via histone modification or DNA methylation influences T cell 
differentiation109,110. In particular, Kagoya et al. showed that CD3+ T cells activated 
with APCs expressing αCD3 mAb, CD80 and CD83 in the presence of JQ1, a 
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specific inhibitor of extra-terminal motif (BET) proteins and bromodomain, supported 
in vitro expansion of TSCM and TCM cells by suppressing Basic Leucine Zipper ATF-
Like Transcription Factor (BATF), an important regulator of CD8+ T cell effector 
differentiation111. These cells maintained functional and transcriptional properties of 
naturally occurring TSCM and TCM, respectively. When infused in NSG mice, JQ1 
treated cells were able to expand, to infiltrate tissues and to reduce tumor burden 
significantly more than cells grown in the absence of JQ1111. 
Collectively, these reports show that it is possible to generate TSCM in vitro 
starting from whole PBMCs or naïve precursors. However, all these protocols have 
limitations. The identification of the molecular signals that are required for the 
differentiation of TSCM cells may have important practical implications for improved 
protocols of ACT. 
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2 AIM OF THE STUDY 
Haplo-BMT combined with pt-Cy is changing the perspective of allogeneic 
transplantation because it allows the identification of suitable donors for patients 
who lack an HLA-matched donor. The mechanisms of T cell recovery following this 
type of successful transplant remain poorly understood. Moreover, it is not clear 
whether pt-Cy spares non-alloreactive T cells and thus favors immune 
reconstitution. The first aim of this work was the identification of the biological 
mechanisms that govern human T cell recovery after haplo-BMT followed by high 
doses pt-Cy.  
We found that TSCM cells with increased immune reconstitution capacity were the 
predominant T cell subet during the early phase of transplantation and 
demonstrated that these cells contribute to the reconstitution of the host by 
generating more differentiated effector cells. As the adoptive transfer of large 
numbers of these cells would be beneficial for immunodeficient patients, including 
HSCT patients, I focused the second part of my work on elucidating the molecular 
mechanisms at the basis of TSCM generation in humans. We focused on the extrinsic 
signals and on the potency of TCR stimulation that are required to block T cell 
differentiation of TN cells while allowing proliferation.  
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3 MATERIALS AND METHODS 
3.1 Cells 
PBMCs isolated from buffy coats and from patient’s peripheral blood were stored 
in liquid nitrogen according to standard procedures.  
3.2 Patients and transplantation procedures 
Clinical and experimental protocol were approved by the IRB of Humanitas 
Research Hospital (Prot. Nr Humanitas 222/14) and Istituto Nazionale Tumori and 
both patients and donors signed consent forms in accordance with Declaration of 
Helsinki. A total of 51 patients were enrolled for haplo-BMT and treated with the 
protocol established by Luznik et al.48 as shown in Figure 2. All experiments were 
performed using randomly selected patients, unless specified (i.e. Ag-specific 
stimulation experiments).  
 
Figure 2. Schematic representation of Luznik’s haploidentical transplantation protocol. 
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3.2.1 Luznik’s transplantation protocol 
The transplant procedures used to treat patients enrolled in this study consist in a 
non-myeloablative T cell replete haplo-identical bone marrow transplantation. 
Briefly, as reported in Figure 2, the patients were prepared with a conditioning 
regimen consisting in 14,5 mg/kg Cy at day -6, -5; Fludarabine from day -6 to day -2 
and low dose total body irradiation (TBI, 200 CentiGray) at day -1. The GVHD was 
controlled by 50 mg/kg Cy administred at days +3, +4 after BMT, Tacrolimus 
(FK506) administred at 1 mg continuously from day+5 until day +180 and 
Mycophenolate Mofetil (MMF) administred at 15 mg/kg 3 times/day from day+5 until 
day +35 after transplant. Granulocyte-colony stimulating factor (G-CSF) was 
administred from day +5 in all patients. 
HLA typing was perfomed in all patients and patient’s relatives. The trasplant was 
considered haploidentical when at least one of the two alleles from donor’s HLA -A, 
-B, -Cw, -DRB1 and DBQ1 loci matched the recipient. The details of the protocol 
can be find in the web-site www.clinicaltrials.gov, protocol numbers NCT02049424 
and NCT02049508. Patients characteristics are listed in Table 1. 
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No. Disease Donor
Sex 
D/R
Age D/R
CMV 
D/R
Disease status 
before 
transplant
Indication 
for 
transplant
aGVHD (grade, 
localization)
aGVHD (therapy)
cGVHD 
(grade, 
localization)
cGVHD 
(therapy)
Infections/Virus reactivations
Follow‐up 
(weeks)
Disease 
status
Reason for stopping 
follow‐up
1 HL Father M/M 52/27 +/+ PR RAA NA NA H1N1 5 NA Deceased
2 HL Son M/F 24/46 +/+ CR TAA - ‐ Non albicans candida 5 CR Graft failure
3 HL Mother F/F 51/19 +/+ CR RAA ‐ ‐ EBV 53 CR End of the study
4 HL Father M/F 52/22 -/+ CR RAA 2, Skin Methylprednisolone Mild, GI tract Budesonide Parainfluenza virus, CMV, EBV 55 CR End of the study
5 NHL  Sister F/M 64/53 +/+ PR RAA - ‐ JC 9 NA Deceased
6 HL Brother M/M 47/45 -/+ CR RAA 2, Skin ECP Mild, Skin Prednisone S. epidermidis, BK, EBV 36 CR End of the study
7 NHL Sister F/F 49/49 +/+ PR RAA AS ‐ CMV 6 PR Consent withdrawal
8 HL Mother F/F 61/33 +/+ CR RAA ‐ ‐ 25 CR Other*
9 NHL Brother M/M 47/45 +/+ CR HR AS NA ESBL E. Coli 5 NA Consent withdrawal
10 NHL Brother M/M 62/57 +/- CR RAA 2, Skin Methylprednisolone ‐ S. aureus, S.epidermidis 13 CR Consent withdrawal
11 HL Brother M/F 29/34 -/- CR TAA 2, Skin ECP ‐ ‐ 50 PD Deceased
12 NHL Son M/F 23/44 +/+ CR TAA NA NA E. faecalis, A. fumigatus 6 NA Deceased
13 NHL Brother M/M 46/54 +/+ PR TAA 1, Skin Tacrolimus ‐ ESBL E. coli, CMV 27 CR Other*
14 HL Son M/F 24/57 -/+ CR TAA - ‐ ESBL E.coli, HHV6 6 CR Graft failure
15 NHL Brother M/F 62/57 +/+ CR RAA AS ‐ C. difficile, CMV, E. coli 9 CR Consent withdrawal
16 HL Mother F/F 60/24 +/+ CR TAA NA NA RSV 4 NA Deceased
17 HL Mother F/M 45/24 +/+ PD RAA - ‐ CMV 8 PD Consent withdrawal
18 NHL Father M/M 51/25 +/+ CR TAA 1, Skin - ‐ ‐ 53 CR End of the study
19 HL Sister F/F 38/47 +/+ CR RAA 1, Skin - ‐ ‐ 36 CR Other*
20 NHL Brother M/M 50/51 -/+ PR Ref - ‐ ESBL E. coli, CMV, BK 23 SD Other*
No. Disease Donor
Sex 
D/R
Age D/R
CMV 
D/R
Disease status 
before 
transplant
Indication 
for 
transplant
aGVHD (grade, 
localization)
aGVHD (therapy)
cGVHD 
(grade, 
localization)
cGVHD 
(therapy)
Infections/Virus reactivations
Follow‐up 
(weeks)
Disease 
status
Reason for stopping 
follow‐up
21 HL Sister F/F 32/28 +/- CR RAA - ‐ ‐ 3 CR Other*
22 HL Sister F/M 21/25 +/- CR RAA AS AS ‐ 4 CR Consent withdrawal
23 HL Mother F/F 54/26 +/+ PR Ref NA NA ‐ 3 NA Deceased
25 NHL Son M/M 35/62 +/- PR RAA 2, Skin ECP Mild, Skin - S. maltophilia, CMV 37 CR End of the study
26 NHL Sister F/F 49/42 +/+ PR RAA 1, Skin - ‐ - 33 CR End of the study
27 HL Cousin M/F 48/40 +/+ PR RAA ‐ CMV, EBV 25 CR Other*
28 HL Father M/F 51/21 -/- PR TAA 1, Skin - NA - 6 PD Consent withdrawal
29 HL Father M/M 51/24 +/+ SD RAallo - ‐ - 4 NA Deceased
31 HL Brother M/F 24/31 +/+ PR RAA - ‐ HSV 12 NA Other
32 HL Father M/M 57/32 +/+ CR RAA - NA CMV, S. epidermidis, P. aeruginosa 9 NA Deceased
33 HL Brother M/M 47/37 -/- SD RAA - NA
E. coli, HHV6, Coronavirus, 
Aspergillus, E. coli
14 PD Deceased
34 AML Mother F/M 63/33 +/+ CR HR - ‐ C. difficile, CMV, BK, H1N1, EBV 51 CR End of the study
35 HL Brother M/M 22/30 +/+ CR RAallo - ‐ CMV 13 CR Consent withdrawal
36 HL Brother M/F 71/66 +/+ CR RAA NA NA CMV 3 CR Deceased
37 NHL Brother M/M 55/54 +/+ CR RAA 1, Skin ECP ‐ E.coli, HSV 51 CR End of the study
38 NHL Cousin F/M 27/35 +/+ CR HR - ‐ HHV6, CMV 20 PD Other*
39 AML Cousin F/M 43/50 +/+ AD Ref NA NA Stenotrophomonas, HHV6 3 AD Deceased
48 ALL Mother F/M 51/24 +/+ CR Ref 1, Skin - NA EBV 9 CR Ongoing
51 NHL Brother M/M 59/55 +/+ CR TAA NA NA - 3 NA Consent withdrawal  
Table 1. Characteristics of the patients enrolled in the study. Abbreviations: HL, Hodgkin 
lymphoma; NHL, non-Hodgkin lymphoma; D/R, donor/recipient; CMV, Cytomegalovirus; M, male; F, 
female; PR, partial remission; CR, complete remission; PD, progressive disease; SD, stable disease; 
RAA, Relapse after autologous; TAA, Tandem autologous-allogeneic; HR, High-risk; Ref, Refractory; 
RAallo, relapse after allogeneic transplantation; NA, not applicable; AS, developed after sampling 
was stopped; ECP, Extracorporeal photochemotherapy; GI, Gastrointestinal; EBV, Epstein-Barr virus; 
JC, John Cunningham polyomavirus; S. Epidermidis, Staphylococcus Epidermidis; BK, BK 
polyomavirus; ESBL E. Coli, Extended-spectrum beta-lactamase-producing Escherichia Coli; S. 
aureus, Staphilococcus aureus; E. faecalis, Enterococcus faecalis; A. Fumigatus, Aspergillus 
Fumigatus; HHV6, Human Herpes Virus 6; C. Difficile, Clostridium Difficile; RSV, Respiratory 
Syncytial Virus S. Maltophilia, Stenotrophomonas Maltophilia; HSV, Herpes Simplex Virus; P. 
aeruginosa, Pseudomonas aeruginosa. Notes: *: the patient stopped coming to the clinic. 
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3.3 Sample collection 
Peripheral blood (25-100mL) and donor BM (5-10mL) samples were collected in 
heparinized tubes in the Haematology and Bone Marrow Transplantation Unit of 
Humanitas Cancer Center. Samples were collected at -d6, d0, d3 (before Cy 
administration), d7, every week until month +3, then every month until one year after 
transplantation (Figure 3). BM was collected during transplant procedures. PBMCs 
were isolated from blood and BM sample using a density gradient centrifugation 
after blood stratification on Ficoll-Paque Premium (GE Healthcare).  
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Figure 3. Schematic representation of sample collection after haplo-BMT. Blood samples were 
collected at the time points here indicated. The number of patients analysed at each time point is 
shown in the bottom row. 
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3.4 Flow cytometry and cell sorting 
Samples were analysed or sorted by flow cytometry and cell sorter using the 
following fluorochrome-conjugated monoclonal antibodies (mAbs, Table 2):  
specificity Ab Clone 
human CD8 RPA-T8 
human CD3 
UCHT1 
HIT-3A 
SP-34.2 
OKT-3 
human CD4 
SK3 
M-T477 
RPA-T4 
OKT-4 
human CD45RA HI100 
human CD14 M5E2 
human CD45RO UCHL1 
human CD27 
O323 
1A4CD27 
human CCR7 150503 
human CD95 DX2 
human CD31 WM59 
human Ki-67 B56 
human CD127 A019D5 
human CD25 M-A251 
human HLA-A*02 BB7.2 
human HLA-A*B07 BB7.1 
human CD57 HNK-1 
human HLA-DR G46-6 
human IFN-g B27 
human IL-2 MQ1-17H12 
human TNF Mab11 
human CD38 HIT2 
human T-bet 4B10 
human Eomes WD1928 
human IRF8 V3GYWCH 
human CD45 H-130 
mouse CD45 30-F11 
Table 2. Fluorochrome conjugated mAbs used for flow cytometry analysis and T cell sorting. 
The specificity (human, mouse), the marker identified by each mAb and the clone are shown. 
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 The following peptide:MHC class I tetramers, were used for Ag-specific 
experiments112: HLA-A*0201/MART26-35 ELAGIGILTV and HLA-A*0201/MART26-35 
EAAGIGILTV, HLA-A*0201/WT37-45 VLDFAPPGA, HLA-A*0201/WT126-134 
RMFPNAPYL, HLA-A*0201/WT235-243 CMTWNQMNL.  
Fluorochrome-conjugated mAbs were purchased from BD, BioLegend and BD 
Bioscences. Some antibodies were conjugated in the laboratory of Dr. Mario 
Roederer from purified unlabelled mAbs (BD). These antibodies were conjugated 
following the protocols reported in the website: http://www.drmr.com/abcon. All 
antibodies were titrated on human PBMCs and used at the concentration giving the 
best signal-to-noise ratio, as described21. For staining and cell sorting, either frozen 
and fresh cells were employed. Frozen cells were thawed in RPMI1640 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin and 
1% L-glutamine (all from Life Technologies) containing 50 U/mL Benzonase 
nuclease (EMD Biochemicals), followed by staining for flow cytometry. 
In all stainings, cells were stained for 15 min at room temperature (RT) with a 
live/dead fixable dead cell stain kit (Life Technologies) to eliminate dead cells. After 
that, cells were stained with for 20 min at RT with a combination of surface mAbs, 
as described21. 
Fluorochrome-conjugated peptide-MHC-I tetramers and chemokine receptor were 
stained by incubating cells at 37°C for 20 min. The Cytofix/Cytoperm kit (BD 
Biosciences) allowed to detect intracellular Ki-67. Intracellular transcription factors 
were detected following fixation of cells with the FoxP3/transcription factor staining 
buffer set (eBioscience). Samples were acquired on a Fortessa flow cytometer as 
shown in Figure 4 and Figure 6 or separated via a flow cytometry Aria III cell sorter 
as depicted in Figure 5 (all machines are from BD Biosciences). Single-stained 
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controls prepared with antibody-capture beads (BD) were used for compensation. T 
cell subsets were defined as shown in Figure 4: recent thymic emigrants (TRTE) 
were CD45RO–CCR7+CD27+CD45RA+CD95–CD31+; TN CD4+ cells were identified 
as CD45RO–CCR7+CD27+CD45RA+CD95–CD31– (for CD8+ T cells, TN were defined 
as CD45RO–CCR7+CD27+CD45RA+CD95–, irrespective of CD31 expression); TSCM, 
CD45RO–CD45RA+CCR7+CD27+CD95+; TCM, CD45RO+CCR7+; TEM, 
CD45RO+CCR7–CD27+; TTM, CD45RO+ CCR7- CD27-; bulk memory T (TMEM) cells: 
CD45RO+ 23.  
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Figure 4. Gating strategy adopted to identify T cell subsets by flow cytometry analysis. 
Fluorescence stability was evaluated over time. Using forward scatter-area (FSC-A) and forward 
scatter height (FSC-H) gate doublets and aggregates were excluded from analysis. CD4+ and CD8+ 
T cells were identified on live/dead- CD14-CD3+cells. Gating on CD4+ T cells, TTE were identified as 
CD45RO–CCR7–; TCM were CD45RO+CCR7+; effector-like cells were CD45RO+CCR7– and further 
distinguished on the basis of CD27 expression as TTM (CD27+) and TEM (CD27–); TSCM were 
CD45RO–CCR7+CD27+CD45RA+CD95+; TRTE were CD45RO–CCR7+CD27+CD45RA+CD95–CD31+; 
TN were CD45RO–CCR7+CD27+CD45RA+CD95–CD31–. For CD8+ T cells, TN were defined as 
CD45RO–CCR7+CD27+CD45RA+CD95–, irrespective of CD31 expression. A similar gating strategy 
was used for CD8+ T cells. 
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TN were purified from whole PBMCs as depicted in Figure 5.  
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Figure 5. Gating strategy used to purify CD8+ TN and bulk TMEM subsets. CD8+ T cells were 
enriched by negative selection from thawed or fresh PBMCs. Time-gated cells were selected as 
singlets on the basis of FSC-A and FSC-H parameters. Live T cells were identified as live/dead-CD3+ 
and lymphocytes on the basis of FSC-A and SSC-A physical parameters. Identification of naïve and 
memory T cell subsets in CD8+ T cells was performed by the use of 4 markers. CCR7 and CD45RO 
allowed the discrimination of naïve-like T cells (i.e., CCR7+CD45RO–) from bulk-memory cells (TMEM). 
CD27 and CD95 markers were used to discriminate TN (CD27+CD95-) from TSCM (CD27+CD95+) cells. 
A similar gating strategy was used to purify T cell subsets from CD4+ population. 
For ACT experiments in mice, CD8+ T cells were identified as shown in Figure 6. 
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Figure 6. Gating strategy used to identify human CD8+ iTSCM infused in NSG mice. The gating 
strategy here shown was used to identify human T cells in peripheral blood and PBMCs isolated from 
mice organs.  
Tmem 
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3.5 Analysis of donor/patient mixed chimerism 
We analysed three patients at the following time points post haplo-BMT: d63, d91 
and d121. DNA was isolated from purified T cell populations (sorted as live/dead-
CD3+CD56-CD20-CD14- T cells) using the Qiamp Mini Kit (Qiagen), according to the 
manufacture’s instructions. The isolated DNA was amplified using a multiples PCR 
fluorescent approach (AmpFISTR Identifiler Plus, Applied Biosystems) on an ABI 
9700 thermal cycler (Applied Byosistem). The reaction was performed to analyse at 
least 3000 cells as described previously113. At least five of these HLA loci were 
amplified using a singleplex Quantitative Fluorescent PCR approach. Primer 
sequence were obtained from the database UniSTS (website: 
www.ncbi.nlm.nih.gov).  
PCR products were run on Capillary Electrophoresis System (ABI310, Applied 
biosystems) and analysed using GENESCAN 3.1.2 software. Single PCR products 
were analysed in electropherograms as peaks variable in length and color. Residual 
mixed chimerism was calculated on the basis of the relative length of donor and 
recipient alleles as describerd previously113. 
3.6 Enumeration of self Ag-specific T cells By MHC class I 
tetramers 
The MHC-I tetramers described in section Methods 2.4 were used to recognize T 
cells with TCRs specific for MART-1 or WT-1 Ags. Given the large numbers of cells 
needed for the quantification of Ag-specific T cells, PBMCs isolated from buffy-coats 
instead of donor’s BM or peripheral blood, were used. Briefly, CD8+ T cells were 
enriched by negative selection (Stem Cell Technologies) and stained with tetramers 
for 15 min at 37°C. Cells were then washed with PBS without calcium and 
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magnesium (referred to as PBS-/-) and stained with mAbs as previously described. 
For each sample, at least 3*106 events were acquired by flow cytometry.  
The threshold of positivity (0.003926 and 0.003705 for MART-1 and WT-1 positive 
fraction respectively; Figure 14) was calculated by analyzing the 75th percentile of 
distributions obtained analyzing tetramer-binding in the CD4+ population (negative 
control). 
3.7 Cell cultures and stimulation of T cells 
3.7.1 In vitro T cell differentiation 
Purified T cells or PBMCs (0.25x106 cells/mL, unless otherwise indicated) were 
cultured in complete RPMI medium (10% FBS, 1% penicillin/streptomycin, 2mM L-
glutamine), and stimulated with αCD3/2/28 antibody-coated beads (Miltenyi). When 
preparing beads bound to αCD3/28 only, the amount of αCD2 in the mix was 
replaced by PBS-/-. Otherwise, cells were activated with plate-bound αCD3 (1µg/mL 
unless indicated; clone OKT3; BioLegend) plus soluble CD28 (1ug/mL unless 
specified; clone CD28.2; BD) in 96 flat-bottomed wells for 9 days. Human cytokines 
(IL-2, IL-12, IL-7, IL-15, IL-18; Peprotech) were pre-titrated, then used at 10 ng/mL, 
unless otherwise indicated.  
3.7.2 Proliferation of T cell subsets 
Cell proliferation was determined by the analysis of 5-(and6)-carboxyfluorescein 
diacetate-succinimidyl ester (CFSE; Life Technologies) dilution23. After CFSE 
staining (5µM, unless indicted), cells were stimulated with IL-15 (Peprotech) for 8 
days at 50 ng/mL, or left in 1 ng/mL IL-15 (non-proliferating control). At the end of 
culture period, cells were harvested and analysed by FACS. Cell number was 
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determined by Trypan blue dye exclusion. When stimulating patient’s PBMCs, 
different time points (n=5; d41, d53, d56, d57 and d65) were used to generate 
Figure 13B. 
3.7.3 PMA/Ionomycin stimulation and T cell cytokine production 
To induce cytokine production, PBMCs were cultured in 96-well plate and 
stimulated with phorbol 12-myrisate 13-acetate (PMA, 10 ng/mL; Sigma Aldrich) and 
Ionomycin (1 µg/mL; Sigma Aldrich) in the presence of Golgi Plug (1 µg/mL; BD 
Bioscences). 4h after stimulation, cells were harvested and analysed by flow 
cytometry. When stimulating patient’s PBMCs, different time points (n=5; d41, d53, 
d56, d57 and d65) were used to generate Figure 13C. 
3.7.4 Co-cultures of purified T cells with auto/allo APCs  
For mixed lymphocyte reaction (MLR) experiments, sorted TN and bulk memory T 
cell subsets were cultured at a ratio of 1:1 with autologous APCs (auto-APCs) or 
MHC-mismatched APCs (allo-APCs) for the times indicated in the text. APCs 
(sorted as live/dead-CD3-CD56-) were purified from PBMCs. Anti-MHC-I (G46-2.6, 
10 µg/mL) and MHC-II (Tu39, 10 µg/mL) blocking antibodies were employed to 
inhibit APC:T cell interactions.  
3.7.5 Stimulation of Ag-specific T cells 
Self Ag-specific T cells were grown by using an accelerated DC maturation 
protocol, as described114. Briefly, at d0, 3.5x106 CFSE-stained PBMCs from HLA-
A*02+ donors were seeded in 48-well plates in AIM-V medium (Life Technologies) 
additioned with FLT-3 (50 ng/mL; DC maturation; R&D) and the Melan-A/MART-1 
peptide variants ELAGIGLTV or EAAGIGILTV (2 µg/mL; peptide chemistry facility, 
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University of Lausanne). 24h after stimulation, IL-1β (10 ng/mL; R&D), PGE-2 (1 
µM; TOCRIS), TNF-a (1U/µg; DC activation mix, R&D) and IL-7 and IL-15 (both at 
10 ng/mL) were included in each well. Cells were collected at day 7 for flow 
cytometry analysis, otherwise restimulated with 2 µg/mL ELAGIGLTV for 18h in the 
presence of Golgi Plug (1 µg/mL; BD Biosciences). 
3.8 Real-time PCR (qPCR)  
Total RNA was isolated from cells with RNeasy Micro Kit (Qiagen) and 
retrotranscribed using High-capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). qPCR was performed with hydrolysis probes: IRF8 (Hs00175238_m1) 
and 18S (Hs99999901_s1) as reference gene (Applied Biosystems) using the ABI 
7900HT Sequence Detection System (Applied Biosystems). miRNA were isolated 
with mirVana kit (Ambion). Mature miR-155 and RNU44 small nucleolar RNA were 
reverse transcribed with specific primers provided by Applied Biosystems and 
TaqMan RT MicroRNA Kit (Applied Biosystems).  
qPCR was performed with miR-155 and RNU44 specific TaqMan primers 
(Applied Biosystems) and Universal PCR Master Mix, No AmpEraseÒ UNG (Roche) 
in MicroAmpÒ Fast Optical 96-Well Reaction Plate (Applied Biosystems) on a 7500 
Fast Real-Time PCR System (Applied Biosystems). Expression levels were 
normalized (∆Ct) to RNU44 or 18S endogenous controls and expression fold 
change relative to CD8+ TN cells were calculated using 2 – (ΔCt sample- ΔCt naive) formula.  
3.9 Confocal microscopy  
iTSCM or iTEff CD8+ T cells washed in PBS-/- were incubated with 500 µl of pre-
warmed Mitotracker Green (25 nM prepared in PBS-/-) for 30 min at 37°C. In the 
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meantime slides were treated to allow T cell adhesion: first incubated with 0.02% 
polylisin (Sigma) for 30 min at RT, than incubated for 3h at 37°C with αCD3 (OKT3 
clone, BD Biosciences; 10 µg/mL in PBS-/-) and αCD28 (CD28.2 clone, BD 
Biosciences; 10 µg/mL in PBS-/-). 0.15x106 cells were attached on slides and 
incubated for 15 min at 37°C. After incubation, cells were immediately fixed with 4% 
Formalin for 10 min, washed twice with 2% BSA in PBS+/+ and once with 2% BSA, 
0.05% tween in PBS+/+.  
Finally, cells were incubated with DAPI (dilution 1:25000 in H2O) for 10 min at RT. 
Slides were acquired with an FV1000 confocal microscope (Olympus). Images were 
analysed with ImageJ (NIH). 
3.10 Mice 
All animal experiments were conducted upon the approval of the Humanitas 
IACUC and the Italian Ministry of Health (protocol 256/2015-PR). NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ (NSG) mice (Jackson Laboratories), bred in SPF conditions, were 
used for adoptive transfer experiments. For all experiments mice were grouped for 
age (5-7 weeks). Briefly sorted CD8+ TN cells were expanded in vitro with αCD3/28-
conjugated beads (T cell activation/expansion kit, Miltenyi; 1 bead:2 cells) in the 
presence of IL-7 + IL-15 (Peprotech; 10 ng/mL each). At d7-8 cells were harvested 
counted and washed twice with sterile saline solution. 1-2x106 CD8+ iTSCM (100 
µl/mouse) were co-transferred by retro-orbital injection with 8x106 PBMCs depleted 
of CD8+ T cells (using anti-APC MicroBeads; Miltenyi). Tail bleeding was performed 
at d16 and d26. Mice were sacrified 1 month after transplantation to avoid GVHD. 
Spleen, lung and liver were collected, tissues were minced and filtered through a 40 
µM cell strainer. 
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3.11 Statistical analysis 
Analysis was performed using GraphPad PRISM (6.0b) and SPICE 5.22 
software. Non-parametric paired or unpaired Wilcoxon rank test and unpaired Mann-
Whitney test were employed to compare two groups. For more than three groups, 
One-Way Analysis of Variance (ANOVA) was used. Spice software was used to 
analyse pie chart differeces (permutation test). P values are two-sided and were 
considered significant when ≤ 0.05. 
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4 RESULTS 
4.1 TN-derived TSCM contribute to immune recovery after 
haploidentical-BMT 
4.1.1 T cell numbers normalize one year after BMT 
The T cell recovery after BMT represents a crucial point for the positive outcome 
of transplant in terms of overall survival, as T cells are the mainly players of GVT 
and host protection from opportunistic infections. We initially evaluated the absolute 
counts of CD3+, CD4+ and CD8+ T cells (Figure 7) as well as of CD4+ and CD8+ T 
cell subsets (Figure 8) over time.  
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Figure 7. T cell recovery in BMT patients over time. Mean±SEM of absolute counts (cells/μl) of 
CD3+, CD4+and CD8+ populations in the first year after haplo-BMT. Abbreviations: MMF, 
mycophenolate mofetil. The number of patients analysed at each time point was previously described 
in section 2.3, Figure 3. 
T cell numbers increased from weeks 6 post haplo-BMT, when the MMF 
immunosuppressive drug was discontinued. After that, cell numbers declined 
equally in CD4+ and CD8+ populations at week 9. Subsequently, T cells numbers 
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progressively increased until 1 year after transplantation (when the sample 
collection stopped). Such increases paralleled the proliferation rate of T cell subsets 
(Figure 9). During the first year, CD4+ and CD8+ memory phenotypes predominated, 
while at the end of the first year post transplantation TN reappeared, probably due to 
restored thymic-output, as assessed by the increase of TRTE cells in CD4 population 
(Figure 8). 
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Figure 8. T cell subsets dynamics following haplo-BMT. Mean±SEM of absolute counts (cells/μl) 
of T cells subests (both CD4+ and CD8+ populations) of patients and donors after transplantation. The 
number of patients analysed in each time point is shown in section 2.3, Figure 3. #=P<0.05 vs 
Donor; Mann-Whitney test. 
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Figure 9. Absolute counts of proliferating CD4+ and CD8+ T cell subsets. Mean±SEM expression 
of Ki-67 by memory T cell subsets during T cell recovery. TRTE and TN cells were not considered as 
they expressed little Ki-67. Week 6 represent the peak of proliferation for all subsets. The numbers of 
patients analysed at each time point is shown in section 2.3, Figure 3. # = P<0.05 vs. Donor; Mann-
Whitney test. 
4.1.2 T cell recovery is donor dependent 
In Luznik’s protocol, patients are prepared with a non-myeloablative conditioning 
regimen and undergo T cell replete haplo-BMT. This means that both donor T cells 
and chemo-resistant host T cells could contribute to immune-reconstitution115. Thus, 
in collaboration with Dr. G. Bulfamante and Dr. B. Cassani we first analysed donor-
recipient chimerism in patients PB within 120 days after transplantation. This 
analysis revealed that more than 98% of cells were of donor origin (data not shown). 
To exclude a possible bias due to a presence of high numbers of donor cells, we 
performed chimerism analysis on sorted live CD3+CD56-CD20-CD14-CD4+ or CD8+ 
from three patients at different time points after BMT (d63, d91 and d126) and 
confirmed that all circulating T cells were of donor origin (Figure 10A). 
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In addition, using flow cytometry and HLA-specific mAbs, we were able to detect 
donor and patient’s T cells over time (HLA-A*02 or HLA-B*07 mismatch; Figure 
10B-C). We observed that, during the first month after BMT, donor and recipient T 
cells coexisted in the patient (Figure 10C), while at 1 month after BMT patients 
displayed 100% donor chimerism (Figure 10B-C). Overall these results suggest that 
only donor T cells contribute to immune recovery, at least in the circulation. 
 
Figure 10. T cell recovery is donor dependent. (A) Proportions of Pt (black) and D (gray) 
chimerism in purified CD4+ and CD8+ T cells. Pies show the median of 3 Pt analysed at d60 after 
haplo-BMT. (B) D (gray) ad Pt (black) chimerism in CD3+ population was confirmed by flow cytometry 
in additional 4 subjects. (C) D and Pt residual chimerism over time. Taking advantage from the HLA 
mismatch between D and Pt CD3+ cells were discriminated using fluorochrome-conjugated mAbs 
directed to a specific HLA (here D HLA-A*02- and Pt HLA-A*02+). flow cytometry analysis were 
performed at indicated time points. 
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4.1.3 Donor TN cells preferentially survive to Cy 
It is well known that in response to Ags or lymphopenia, T cells undergo 
massive proliferation and generate effector cells characterized by the lack of CCR7, 
CD45RA and acquisition of CD45RO expression22,52. Thus, we analysed if this was 
also the case in our cohort and we observed that, at d3 after BMT, the vast majority 
of circulating CD3+ T cells expressed activation (HLA-DR) and proliferation (Ki-67) 
markers (Figure 11A-B). Moreover, these cells acquired a CCR7-CD45RO+ effector 
phenotype, irrespectively of their original differentiation status (i.e. TN, TSCM, TCM or 
TEM phenotype) (Figure 11B). As described before44, Cy preferentially depletes 
proliferating cells. Following the administration of Cy in vivo at d3 and d4 after 
transplantation, we observed that Ki-67+ cells disappeared after Cy administration 
(Figure 11A). Only a proportion of relatively quiescent cells was spared by Cy 
(Figure 11A). Fine analysis of Ki-67 expression along with the differentiation status 
of T cells revealed that the vast majority of circulating CD4+ and CD8+ TN cells were 
quiescent before Cy administration, indirectly suggesting that they are less sensitive 
to Cy (Figure 11C). In contrast, memory T cells expressed high levels of 
proliferating Ki-67 marker (Figure 11C). Given that only donor T cell contribute to 
immune-recovery, we extensively analysed the phenotype and maturation status of 
recipient and donor T cells by 18-color flow cytometry before the initiation of 
reconstitution (i.e., at day 7). Patients T cells preferentially expressed a memory 
phenotype (with some differences between CD4+ and CD8+ populations in terms of 
TCM, TEM, TTE subsets distribution) with high levels of activation (HLA-DR) and 
senescence (CD57) markers (Figure 11D). In contrast, donor T cells displayed a 
TSCM phenotype (CCR7+, CD45RA+, CD27+, CD45RO-, CD95+) and expressed low 
levels of activation (HLA-DR) and senescence (CD57) markers (Figure 11D). The 
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frequency of TSCM among the donor CD4+ and CD8+ populations largely exceeded 
that observed in the infused grafts (Figure 11E) and in peripheral blood of healthy 
controls (2-3%)15. Collectively, these results suggest a possible contribution of CD4+ 
and CD8+ TSCM in T cell recovery after BMT.  
 
 
Figure 11. Donor TN cells preferentially survive to Cy. (A) Representative (out of 10) activation 
(HLA-DR) and proliferation (Ki-67) marker expression in donor (D) and patient (Pt) CD3+ T cells at 
the time point indicated. (B) Surface markers CCR7/CD45RO, HLA-DR and Ki-67 expression in 
donor (D) and patient (Pt) CD8+ T cells 1 month after transplantation.  
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(C) Mean±SEM of frequency (n=22, each dot represent a patient) of proliferating Ki-67+ T cell 
subsets at d3 after haplo-BMT in CD4+ and CD8+ population. +, *: P<0.05 vs TRTE and TN 
respectively; Wilcoxon test. (D) Donor derived (D, red, HLA-A*02-) and patient (Pt, dark grey, HLA-
A02+) CD4+ and CD8+ T cells were identified in patient’s peripheral blood by flow cytometry. Then a 
simultaneous flow cytometry analysis of differentiation (CCR7, CD45RA, CD27, CD45RO, CD95), 
activation (HLA-DR), senescence (CD57) and proliferation (Ki-67) markers was performed. Light grey 
cells in the background are CD4+or CD8+ T cells from peripheral blood of healthy controls. 
4.1.4 Post-transplant TSCM originate from infused donor TN cells 
All memory T cells, including TSCM, identified in the circulation of patients were 
proliferating before Cy administration. Thus, because Cy depleted preferentially 
proliferating T cells, it seems unlikely that the high numbers of TSCM at d7 originated 
from TSCM that were transferred with the graft and that survived Cy (Figure 11C). 
We then supposed that TSCM could originate from TN infused with the graft. To 
confirm this hypothesis, we focused our attention on a specific TN subset of CD4+ 
population, the TRTE, identified by the surface expression of CD31 along with naïve 
markers. These are early differentiated TN cells that recently egressed from the 
thymus. Upon T cell activation and differentiation into memory, CD31 is rapidly 
downregulated, therefore TSCM and memory T cells do not express CD3115. CD8+ T 
cells were not studied in this regard, as CD31 does not identify CD8+ TRTE. After 
transplantation almost all patients’ T cells displayed a memory phenotype, thus 
obviating the necessity to discriminate donor’s from patient’s CCR7+CD45RO- 
naïve-like (NL) T cells to follow CD4+ TRTE (Figure 11D).  These NL cells also 
expressed naïve markers like CD45RA and CD27 (data not shown). NL-CD4+ T cell 
in the graft were predominantly CD95-, but acquired progressively CD95 expression 
both in CD31- and CD31+ fraction, over time (Figure 12A). This differentiation was 
not due to the presence of Cy, as we demonstrated that Mafosfamide (the active 
form of cyclophosphamide, used in vitro) did not affect T cell phenotypes in vitro 
(data not shown). At d7 after BMT, the percentage of CD31+ TSCM was similar to 
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CD31+ TN fraction adoptively transferred with the graft (Figure 12B). We supposed 
that the high amount of cytokines and inflammatory molecules due to the 
lymphopenic environment and transplantation conditions (i.e. non myeloablative 
preparative regimen), triggered TN cell differentiation.  
Previous reports performed in mice showed that memory cells are more resistant 
to Cy treatments49,116. To better clarify the mechanism involved in the resistence to 
Cy activity we performed in vitro experiments using MLR cultures of highly purified 
TN or memory T cells with allo/auto-APCs. In the presence of allo- but not auto-
APCs, TN cells were highly activated (CD25+), underwent proliferation (i.e., diluted 
CFSE) and upregulated CD45RO expression within 3 days after activation (Figure 
12C). These data suggest that Ki-67+ memory fraction depleted by Cy 
administration in patients contained also activated allo-reactive TN cells. Finally, we 
investigated whether TN differentiation was a consequence of the lymphopenic or 
allogeneic environment. As expected, in vitro incubation of TN with allo- but not auto-
APCs induced CD95 upregulation in the non-alloreactive fraction (defined as 
negative for both CD25 and CD69 activation markers, here not shown). Moreover, 
CD95 expression was curtailed when using MHC-I or MHC-II blocking antibodies 
indicating that allogeneic environment could play an important role in the acquisition 
of the TSCM phenotype (Figure 12D-E). 
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Figure 12. Post-transplant TSCM originate from infused donor TN cells. (A) Representative (out of 
12) CD31 and CD95 expression on naïve-like (CCR7+CD45RO-, NL) CD4+ T cells from donor’s (D) 
bone marrow (BM) and peripheral blood (PB) and patient’s (Pt) PB at indicated time points after 
haplo-BMT. (B) Mean±SEM of CD31 expression in circulating CD4+ TN and TSCM from donor’s BM 
and patient’s PB at d7 after transplantation. *:P<0.05, Wilcoxon test.(C) CFSE dilution, memory 
marker CD45RO and activation marker CD25 expression by CD8+ TN and TMEM after incubation with 
auto/allo-APCs for 3 days. Black gate and black line identify proliferating CFSElow T cells. Grey gate 
and line identify non proliferating CFSEhigh T cells.(D) Representative analysis of CD95 expression on 
CD4+ and CD8+TN cells incubated with different stimuli indicated in the legend. (E) Summary of the 
data obtained in (D). CD95 MFI is normalized against TN + autoAPC culture condition (dotted line=1); 
n=8, from 4 independent experiments. *=P<0.05. 
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4.1.5 Post-transplant TSCM are true memory cells 
In order to understand whether TN-derived TSCM possess functional capabilities of 
memory T cells, we tested the ability of TSCM to proliferate in response to IL-15 and 
to produce effector cytokines after PMA/Ionomycin stimulation. We first tested these 
approaches  on T cells isolated from blood samples collected early after 
transplantation. However, cells were not able to respond to IL-15 or PMA/Ionomycin 
until d40 post BMT (data not shown). This was probably due to the 
immunosuppressive therapy (MMF + Tacrolimus) administered to patients until d35. 
To overcome this problem, we repeated experiments with cells isolated from blood 
samples collected at later time points (i.e. from d41 to d65). At these time points, the 
cell numbers were too low for FACS sorting. In previous experiments, we showed 
that IL-15 stimulation does not affect the phenotype of TSCM cells15. This allowed us 
to perform experiments by stimulating whole PBMCs in vitro. After IL-15 stimulation, 
TSCM from patients (d41-d65 post BMT) diluted CFSE similarly to memory T cells 
(Figure 13A-B). In line with their identity, TN cells were not able to proliferate in 
response to IL-15 (Figure 13A-B).  
To further demonstrate that donor TN-derived TSCM possess memory features, we 
stimulated PBMCs from haplo-BMT (d41-d65) with PMA/Ionomycin and evaluated 
their cytokine profile by flow cytometry analysis. Upon PMA/Ionomycin stimulation 
the proportion of T cell subsets among CD4+ and CD8+ population did not change 
(data not shown). TSCM produced a combination of IFN-g, IL-2 and TNF-a similarly to 
naturally occurring TSCM, but distinct from the cytokine profile of TN and memory T 
cells from healthy controls (Figure 13C). Collectively these data show that donor 
TN-derived TSCM acquire memory properties after haplo-BMT in vivo. 
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Figure 13. Post-transplant TSCM are true memory cells. (A) Frequencies of CFSElow cells in each 
CD8+ T subsets from a representative healthy donor (HD) and patient (Pt) at d41 post haplo-BMT. 
Whole PBMCs from HD and Pt were cultured with 1 ng/mL (grey histogram, non proliferating control) 
or 50 ng/mL (black histogram) of IL-15 for 8 days. In Pt, CD95– TN were not detected (N/D) ex vivo or 
after stimulation with IL-15. TMEM: CD45RO+ memory T cells. (B) Summary of 3 independent 
experiments (n=6) as described in A. The mean±SEM of CFSElow CD8+ T cell subsets is shown. *= 
P<0.05; Mann-Whitney test. (C) Pies show the intracellular cytokine profile (IFN-g, IL-2 and TNF-a) 
following PMA/ionomycin stimulation for 4 hr in gated TSCM from patients (n=3; at d35, d42 and d49 
post haplo-BMT) and in T cell subsets from healthy donors (HD; n=4). *=P<0.05; permutation test. 
66 
 
 
4.1.6 Persistence and memory differentiation of adoptively-transferred TN 
Next, we investigated the capability of donor TN-derived TSCM that survived to Cy 
treatment to contribute to immune recovery. Should this be the case, antigen-
specific TN cells infused with the graft that are non allogenic would be found in the 
memory compartment during the recovery phase. The frequency of antigen-specific 
T cells in the TN comparment is usually very low, i.e. between 1/105 and 1/106 cells, 
however T cells specific for some self/tumor-associated antigens including MART-1 
and WT-1 are relatively high because they can escape negative selection in the 
thymus117,118, thus allowing their measurement with standard flow cytometry and 
p:MHC-I tetramers. We first excluded that new generation of TN cells by the thymus 
could confuse these data, as TREC levels in a subset of individuals receiving h-
HSCT was undetectable up to 6 months post transplantation (not shown). As 
expected, MART-1 and WT-1 specific CD8+ had a naïve phenotype in healthy 
donors (Figure 14A-C). After infusion, both MART-1 and WT-1 specific T cells were 
able to persist in the host up to d90 after BMT (Figure 14B) and acquired a 
CD45RO+CCR7-CD95+ phenotype as soon as d45 after BMT for MART-1 (Figure 
14C). These data suggest that Ag-specific TN cells survive to pt-Cy treatment and 
contribute to immune recovery of the T cell compartment. 
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Figure 14. Persistence and memory differentiation of adoptively-transferred TN. (A) Phenotype 
and percentage of MART-1 (red dots) and WT-1 (blue dots)-specific CD8+ T cells identified by MHC 
class I tetramers in 1 representative donor (D) and the corresponding patient (Pt). Numbers indicate 
the frequency of cells in each gate. In light grey total CD8+ T are shown. (B) Summary of the 
mean±SEM of the MART-1 and WT-1 specific CD8+ T cells shown in (A). (C) Frequency of MART-1 
and WT-1 specific CD8+ T cells with a TN-phenotype in Ds and Pts at time points indicated after 
transplantation. *=P<0.05, Mann-Whitney test. 
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4.2 Generation of TN-derived TSCM (iTSCM) for ACT 
Results obtained in the first part of this work suggest the non-redundant role of 
donor TN-derived TSCM in immune reconstitution. Moreover, in previous reports, 
adoptive transfer of selected T cell subsets in mice and non-human primates 
showed that  less differentiated T cells are endowed with superior anti-tumor, self-
renewal, multipotency and persistence capabilities compared to more differentiated 
subsets (see chapter 1.1)119,120,93,92,54. Because the low numbers of TSCM in the 
peripheral blood limits their clinical application, the possibility to expand this 
population in vitro represents a promising approach for the improvement of ACT. 
For this reason, in the last part of this work, we optimized a method to generate high 
numbers of fully functional TSCM from naïve CD8+ precursors in vitro, and at the 
same time, investigated the molecular mechanisms involved in their generation. 
4.2.1 Curtailed T cell receptor stimulation in combination with IL-7 and IL-15 
generates TSCM cells.  
We first evaluated the effect of different combination of cytokines, and potency of 
TCR activation on the differentiation of highly purified human CD8+ TN cells (isolated 
from peripheral blood) as assessed by surface expression of CD45RO and CCR7. 
We decided to stimulate cells with a low bead:cell ratio (i.e. 1:2), as previous report 
showed that higher bead:cell ratio (3:1) induced the acquisition of CD45RO 
expression in TN cells 37. Overall, IL-7 and IL-15 combined with αCD3/28 was the 
best combination to maintain a CD45RO–CCR7+ phenotype (Figure 15A) and to 
generate bona fide CD45RO-CD45RA+CCR7+CD27+CD95+ TSCM-like cells (Figure 
15B; hereafter referred to as iTSCM).  
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By contrast, a stronger TCR stimulation with αCD3/2/28 in the presence of IL-
7/IL-15 or IL-2 preferentially generated CD45RO+CCR7+ TCM-like cells (Figure 15A-
C).  
IL-2 alone or in combination with IL-18 had limited effects on T cell differentiation, 
while the addition of IL-12 to IL-2 induced the generation of bona fide 
CD45RO+CD45RA–CCR7–CD27intCD95+ T effectors (iTEff) (Figure 15A-B). 
Compared to iTEff, iTSCM displayed lower expression of Ki-67 (indicative of 
proliferation), CD38 and HLA-DR (indicative of activation) markers and showed a 
lower size (indicated by forward-scatter, FSC-A) (Figure 15B). A summary of the 
phenotypes induced by selected culture conditions is shown in Figure 15C. Overall, 
increasing TCR stimulation through the addition of CD2 to the culture conditions, 
resulted in an increase of the frequency of dead cells at the end of culture period 
(Figure 15D). In iTEff condition, this was compensated by increased proliferation 
(Figure 15E). Despite the lower activation and proliferation status compared to iTEff 
in vitro, iTSCM cells expanded robustly over time in vivo following adoptive transfer 
into NSG mice (Figure 15F) and infiltrated multiple organs, including the spleen, the 
liver and, at a lesser extent, the lung (Figure 15G).  
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Figure 15. Curtailed T cell receptor stimulation in combination with IL-7 and IL-15 generates 
TSCM cells. (A) Representative flow cytometry analysis of surface marker expression (CD45RO, 
CCR7) in ex vivo PBMCs and in sorted CD8+ TN cells following culture with different combination of 
cytokines and T cell receptor (TCR) stimulations for 11 days. (B) Sorted CD8+ TN cells were cultured 
in aCD3/28+IL-7/15 (iTSCM) or aCD3/2/28+IL-2/12 (iTEff) for 11 days as in (A). The expression of 
naïve and memory markers in the two conditions (black line=iTSCM; dotted line= iTEff; light grey full 
histogram=total CD8+ T cells, used as control) is shown; n=4 for all parameters with the exception of 
n=2 for Ki-67, CD38 and HLA-DR markers. (C) Mean±SEM of frequencies of CD8+ T cells with the 
TSCM, TCM, TEM and TTE phenotypes, after culture in the indicated conditions (aCD3/28+IL-7/15: n=22; 
aCD3/2/28+IL-7/15: n=9; aCD3/2/28+IL-2/12: n=12) for 11 days was determined by flow cytometry. 
(D) Mean + SEM of the frequencies of live cells and (E) fold expansion in cell number, compared to 
baseline, of sorted CD8+ TN cells cultured as in C. (F, G) Human CD8+ TN stimulated with 
aCD3/28+IL-7/15 for 8 days were transferred into NSG mice. (F) Tail bleeding was performed at 
indicated time points, human CD8+ infused cells were identified as described in Figure 6 and 
absolute counts were evaluated by flow cytometry analysis. (G) The absolute counts described in (F) 
were determined also in tissues and organs isolated from sacrificed mice. Data shown as 
mean±SEM of 5 replicate mice, one single experiment. * P<0.05, ** P<0.01 and *** P<0.001, 
Wilcoxon test. 
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4.2.2 Polyclonal iTSCM cells are early-differentiated memory cells.  
The capability to produce specific combination of cytokines upon PMA/Ionomycin 
stimulation depends by the degree of memory differentiation22. Less differentiated T 
cells mainly produce IL-2 and TNF-a while more differentiated ones mainly produce 
IFN-g22. We therefore reasoned that iTSCM and iTEff had different patterns of cytokine 
production. We stimulated iTSCM and iTEff (d12) with PMA/Ionomycin (P/I) for 4 hours 
in the presence of Glolgi Plug. iTSCM produced mainly TNF-a and IL-2, either alone 
or in combination but little IFN-g, while iTEff produced the 3 cytokines together 
(Figure 16), thereby indicating that iTSCM are early differentiated memory cells. 
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Figure 16. Polyclonal iTSCM cells are early-differentiated memory cells. (A) highly purified CD8+ 
TN cells were stimulated as in Figure 15C to generate iTSCM and iTEff. After 7 days, cells were 
harvested and stimulated with PMA/Ionomycin (P/I) for 4h in the presence of Golgi Plug. 
Unstimulated cells (ns) were included as negative control. IL-2, IFN-γ and TNF-a production was 
evaluated by flow cytometry. 
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4.2.3 Ag-specific iTSCM are functionally and phenotypically similar to 
polycolonal iTSCM  
To understand whether the same pattern of cytokine production shown in Figure 
16, could be observed at the Ag-specific level, we used an accelerated DC 
maturation protocol114 to generate high numbers of CD8+ MART-1 specific iTSCM 
from TN precursors. To do this, we stimulated whole PBMCs from HLA-A*02+ donors 
with the native, 10-mer MART-1 peptide EAAGIGILTV, or its heteroclitic variant 
ELAGIGILTV, that is capable to bind cognate TCRs with higher avidity (hereafter 
named EAA and ELA, respectively). Both peptides induced proliferation of the Ag-
specific CD8+ cells, as assessed by CFSE dilution (Figure 17A). However, ELA 
induced either higher frequencies and total numbers of MART-1 specific TSCM cells 
compared to EAA stimulation (Figure 17B). Restimulation of ELA- or EAA-primed T 
cells with ELA-peptide (2 µg/mL) at d7, induced the production of cytokines shown 
in Figure 17C. The profile was similar to that produced by iTSCM generated by 
aCD3/28 beads and restimulated with P/I (Figure 17D). These results suggest that 
the generation of Ag-specific TSCM is comparable to polyclonal iTSCM both at the 
phenotypical and functional level. 
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Figure 17. Ag-specific iTSCM are functionally and phenotypically similar to polycolonal iTSCM. 
(A) HLA-A*02+ PBMCs from healthy controls were stimulated with a cocktail of cytokines (including 
FLT-3, IL-1β, PFE2 and TNF-a) to induce maturation of dendritic cells (DC). ELA or EAA peptides 
were added to induce activation and expansion of MART-1 specific T cells. The presence of IL-7 and 
IL-15 sustained differentiation through TSCM phenotype. Representative frequencies (assessed by 
flow cytometry) of CFSE dilution of MART-1 specific T cells at different culture conditions (top; no 
peptide= ELA or EAA were not added to the culture) and CD45RO/CCR7 expression in MART-1 
specific T cells (black dots) superimposed to total CD8+ T cells from the same culture (bottom) are 
shown. Data are representative of n=9 donors from 4 independent experiments. (B) Mean+SEM of 
the percentage of MART-1 specific on total CD8+ cells (left; ELA: n=6; EAA: n=9) and the relative 
TSCM count (right; ELA: n=6; EAA: n=5) following peptide stimulation. Relative TSCM count was 
calculated only when the total number of cells within the MART-1 positive fraction was >15. (D) 
Summary of the results of cells stimulated as in (A) with PMA/Ionomycin (P/I) and in (B) with 
ELA/EAA peptides. For all conditions IL-2, TNF-a and IFN-γ production was evaluated by flow 
cytometry. Data are shown as mean+SEM. The number of healthy controls used for each experiment 
is shown in the legend and derive from 5 independent experiments. The legend refers to the initial 
stimulation at day 0 and to the restimulation at day 7 (either ELA peptide or P/I). In all flow cytometry 
plots, values indicate percentage of cells within the gate. * P<0.05 vs. iTSCM, Wilcoxon test. 
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4.2.4  iTSCM cells undergo limited activation and effector differentiation.  
In order to better understand the molecular mechanisms involved in TSCM 
formation, we quantified effector molecules production, both at the protein and 
mRNA level. Specifically, we investigated two transcription factors (TF): T-bet and 
Eomes. These TF increase progressively with T cell differentiation and control 
effector functions of T cells 121,122. Moreover we investigated also IRF4123, IRF8124 
and miR-155125. The expression of these molecules is regulated by the potency of 
TCR activation. Accordingly, T-bet and Eomes increased progressively with the 
duration of the culture period (Figure 18A), while IRF4, IRF8 and miR-155 were 
mostly detected during the first days of culture, then their expression waned (Figure 
18B). All these molecules showed a higher expression in iTEff compared to iTSCM 
throughout the stimulation period, thus recapitulating the differential activation status 
observed in Figure 15B.  
It has also been proposed that the content of mitochondria increases along the 
differentiation of T cells126. Accordingly, confocal microscopy analysis revealed that 
iTSCM harboured fewer mitochondria and appeared to have little cytoplasm 
compared to iTEff  (Figure 18C), thus corroborating the lower size observed in 
Figure 15B.   
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Figure 18. iTSCM cells undergo limited activation and effector differentiation. (A, B) highly 
purified CD8+ TN cells were activated with aCD3/28+IL-7/15 (iTSCM condition) or aCD3/2/28+IL-2/12 
(iTEff condition). The expression (shown as mean + SEM) of effector molecules was evaluated by flow 
cytometry (n=3; T-bet, Eomes, IRF4; expressed as median fluorescence intensity or MFI) or by RT-
qPCR (n=4; Irf8, miR-155 expression reative to S18 house keeping gene). h:hours; d, days. * P<0.05 
vs. iTSCM, Wilcoxon test. (C) Confocal microscopy analysis (100x magnification) of mitotracker green 
(green=mitochondria) and DAPI (blue=Nuclei) in iTSCM cells and iTEff cells generated from CD8+ TN 
cells as in (A). Picture shows cells from 2 different healthy controls. Similar data were obtained from 
2 additional individuals. Scale bars, 10 µm. 
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4.2.5 Curtailed CD3 but not CD28 stimulation contributes to iTSCM formation 
 Using a low bead:cell ratio TN were less activated and did not upregulate the 
memory marker CD45RO. However, it is difficult to determine the specific 
contribution of CD3 or CD28 molecules to T cell differentiation in this model. For this 
aim, we stimulated CFSE labeled TN cells in TSCM-promoting conditions (i.e., with IL-
7 and IL-15) and in the presence of titrated amounts of plate-bound aCD3 and 
soluble aCD28, then we assessed naïve (CCR7, CD45RA, CD27) and memory 
(CD45RO, CD95) markers expression (Figure 19A-C). It is well known that T cell 
differentiation strongly correlates with T cell proliferation127. As different strengths of 
TCR stimulation result in differential proliferation, analysis of specific markers was 
performed according to the level of CFSE dilution (i.e., generations). Analyses were 
performed when >50 cells were available in each gate (Figure 19A-C). Different 
amounts of aCD28 had no impact on T cell differentiation (not shown), while 
decreasing concentrations of aCD3 resulted in the progressive shift of proliferating 
cells towards a CD45RA+CD45RO– phenotype (Figure 19A-B). These cells also 
maintained the expression of CCR7 and CD27 and de novo expressed CD95 
(Figure 19C), confirming that curtailed TCR stimulation limits T cell differentiation 
and favors the generation of TSCM cells.  
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Figure 19. Curtailed CD3 but not CD28 stimulation contribute iTSCM formation. (A) 
Representative flow cytometry analysis of CD45RO (top) and CD45RA (bottom) in CFSE-diluting 
CD8+ TN cells following stimulation with different concentrations of plate-bound aCD3 and 5 µg/mL 
soluble aCD28. (B) Heat map of data as in (A) according to CFSE generation (n=1-4, gates were not 
take into consideration when count/cycle was<50; grey box: data not available due to the low cell 
count). (C) Frequencies of marker expression of human CD8+ TN cells stimulated with different 
concentrations of plate-bound aCD3 (indicated in the legend) and soluble aCD28 (5 µg/mL). The 
expression of the indicated markers was evaluated in different CFSE peaks (generation #) by flow 
cytometry. * P<0.05 vs. 5 µg/mL aCD3, Wilcoxon test.  
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4.2.6 Self-renewing capability and multipotency of iTSCM cells.  
 Naturally-occurring TSCM are known to preferentially self-renew in vitro and in 
vivo compared to TCM and TEM, while simultaneously capable to generate more 
differentiated cells 128,24,15. To assess both these aspects respectively, iTSCM were 
collected at d7 after stimulation, stained with CFSE and induced to proliferate in 
response to the homeostatic cytokine IL-15 (50ng/mL, while 1ng/mL IL-15 was used 
as negative control) or to aCD3/2/28 beads + IL-2 and IL-12 (iTEff-polarizing 
condition). Similarly to ex vivo TSCM and bulk memory cells (sorted as CD45RO+, 
TMEM), iTSCM proliferated in response to IL-15, while TN remained quiescent as 
expected (Figure 20A). A summary of CFSE dilution from 4 healthy controls is 
shown in Figure 20B. While the vast majority of iTSCM maintained their original 
phenotype upon in IL-15 stimulation (Figure 20C), those in iTEff-polarizing condition 
differentiated to CD45RO+CCR7+ TCM and CD45RO+CCR7– TEM cells (Figure 20D), 
thus indicating self-renewal capacity and multipotency, respectively.   
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Figure 20. Self-renewing capability and multipotency of iTSCM cell. (A) iTSCM (generated as in 
Figure 15C) and purified TN, TSCM and total memory T (TMEM; defined as CD45RO+) CD8+ T cells 
were incubated with IL-15 for 12 days (50ng/mL, black line histogram). CFSE dilution, indicative of 
cell proliferation, was evaluated by flow cytometry. Filled grey histograms indicates unstimulated 
control (IL-15 1ng/mL). (B) Summary of the frequencies of proliferating iTSCM cells (CFSElow) shown 
in (A) are depicted as mean±SEM (n=4 individuals from two independent experiments). * P<0.05 vs. 
control (CTRL), Wilcoxon test. (C) Percentage of T cells with a TSCM phenotype (out of total CD8+ T 
cells), after stimulation of TN in iTSCM condition cultures (described in Figure 15C; pre-IL-15) and after 
additional 12 days of stimulation with IL-15 (post-IL-15; IL-15 50ng/mL). Frequencies are shown as 
mean±SEM of n=4 healthy individuals from 2 independent experiments. (D) CFSE dilution (top) and 
CD45RO/CCR7 expression following aCD3/2/28 + IL-2 and IL-12 stimulation (iTEff conditions; 
bottom) of iTSCM cells generated as in Figure 15C was measured by flow cytometry. Data shown are 
representative of measurements made for 3 samples from two independent experiments. 
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5 DISCUSSION AND CONCLUSIONS 
CD8+ TSCM cells are rare, antigen-experienced cells. Among memory cells, TSCM 
represent the subset endowed with superior immune-recovery, anti-tumor, self-
renewal, multipotency and persistence capabilities, in mice and non-human 
primates54,92,93,119,120. However, their role in human settings it has not been 
demonstrated. Thus, we investigated the immune recovery of T cell subsets in the 
contest of Haplo-BMT followed by pt-Cy. Haplo-BMT with pt-Cy has recently been 
introduced as an approach that provides a donor for nearly all patients lacking an 
HLA-matched donor. On one hand, the presence of T cells infused with the graft 
enhance graft versus tumor (GVT) effects50. On the other hand, in vivo T cell 
depletion by pt-Cy and immunosuppressive regimen adopted to reduce GVHD, can 
lead to severe infections52. It is unclear how pt-Cy works as regards the transfer of 
immunity from donor to recipient. Here, we showed a nonredundant role of donor 
TN-derived TSCM in human T cell reconstitution after haplo-BMT and pt-Cy 
administration, both at the polyclonal and Ag-specific level. A proposed model of the 
events occurring in this scenario is depicted in Figure 21. 
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Figure 21. Proposed mechanism for immune reconstitution following haploBMT with non-
myeloablative conditioning regimen and high-dose Cy after transplant, and in vitro TSCM 
generation from TN precursors for ACT. Donor BM–derived haematopoietic stem cells, lymphoid 
precursors, TN and TMEM are infused with the graft. Haematopoietic stem cells and lymphoid 
precursors survive pt-Cy and contribute to T cell reconstitution months after BMT. Conversely allo-
reactive, activated and proliferating (HLA-DR+, Ki-67+)TMEM and TN cells are depleted by pt-Cy. 
Quiescent TN spared by Cy rapidly differentiate into TSCM as soon as d7 after haplo-BMT. In the 
following weeks, naïve-derived TSCM are able to expand in response to self/tumor antigens (Ags) or 
homeostatic expansion, thus generating TMEM. Donor TN cells could be employed for ACT after in vitro 
TSCM formation and expansion. This could contribute to faster immune recovery, protection of patients 
from opportunistic infections and increased GVT. 
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It is important to note that only donor T cells are responsible for immune 
recovery. It can be speculated, therefore, that the composition of the graft in terms 
of presence of different T cell subsets shapes subsequent immune recovery. 
Multiple studies have been conducted in this regard in clinical protocols over that the 
one investigated here, with somewhat contrasting results. I demonstrated with my 
work that both antigen-specific TN (Figure 14) and memory T cells (published in 
Roberto et al.129; here not shown) survive pt-Cy and contribute to immune recovery, 
thus justifying future analysis of the influence of graft composition on adverse event 
development and disease progression. It should be noted however, that the rate of 
alloreactivity between donor and recipient, and thus the depletion of infused cells by 
pt-Cy cannot be predicted ex vivo. Therefore, pt-Cy treatment may play a 
confounding role in this regard. 
Extensive analysis of T cell subsets during the first week after transplantation 
revealed that nonalloreactive TN preferentially survived to pt-Cy, which were 
unexpectedly outnumbered by TSCM -phenotype cells cells at d7 (Figure 11). 
Conversely, as much as 70% of memory/effector T cells were proliferating at d3 
after transplantation and were subsequently depleted by pt-Cy (Figure 11). Our 
experiments showed that both TN and memory T cells proliferated when stimulated 
with allo-APCs in vitro and that TN rapidly upregulated the memory marker 
CD45RO, thus suggesting that the proliferating memory/effector cells detected at d3 
in vivo also include T cells that originated from both compartments (Figure 12).  
TSCM cells represented the dominant donor T cell subset in the circulation after pt-
Cy and we hypothesized they could originate from the TN infused with the graft. 
Recently Cieri et al. suggested that the posttransplant lymphopenic environment 
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may favour the generation of TSCM from naive precursors37. In line with these results, 
we observed that the acquisition of CD95 expression by TN could be induced in a 
culture condition mimicking the allogeneic stimulation occurring in vivo (Figure 12). 
A weak point of the current study is that the differentiation of TSCM from TN 
precursors could not be demonstrated in vivo at the clonal or Ag-specific level due 
to the paucity of T cells that could be recovered in the post-transplant setting. 
However, experiments conducted with polyclonal T cell populations (Figure 12) 
supported the concept that TN can generate TSCM cells in the context of allo-
recognition. In line with our observations Cieri et al. showed that the TCRB 
sequences of TN sorted from leukapheresis product (LP) were found in all memory 
subsets isolated from peripheral blood of Pts at d30 after transplantation, suggesting 
that TN are able to generate all subsets of more differentiated cells, including TSCM. 
Moreover, the authors observed that sequences present in LP-TCM were found 
preferentially in TCM and TEM/TEFF repertoires at d30 after transplant, whereas less 
than 10% were found in the TSCM repertoire. Sequences retrieved in LP-TEM/EFF were 
found mainly within d30 TEM/TEFF, although conversion into TCM was also observed 
(27%). Again, less than 10% of TCRB sequences identified in LP-TEM/TEFFwere 
retrieved in the TSCM compartment at d30. These and our data support a progressive 
model of differentiation according to the relationship TNàTSCMàTCMàTEMàTEFF. 
Although only T cells isolated from PB could be analysed for ethical reasons, 
expansion or redistribution of pre-existing donor TSCM from lymphoid tissues seems 
unlikely, given the preferential depletion of proliferating cells by Cy administration 
and the virtual absence of TSCM in the infused BM, respectively.  
Our experiments indicate that MART-1 and WT-1 specific TN cells infused with the 
graft survived pt-Cy, persisted in the patient and subsequently generated memory 
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cells (Figure 14). Self Ag-specific memory cells are rarely observed in the 
peripheral blood of healthy individuals. As regards to MART-1, specific-memory 
cells were observed in metastatic melanoma patients, but not in healthy 
individuals15,130, thus suggesting a role of Ag, inflammatory cytokines and 
costimulation in their generation131. Similar results were obtained in the context of 
tumors over-expressing WT-1132. it has also been shown that TN cells can 
differentiate into memory cells in the absence of antigenic stimulation, rather in 
response to the lymphopenic environment (i.e., increased levels of homeostatic 
cytokines IL-2, IL-7 and IL-15)40,133. Further studies are required to clarify whether 
increased availability of homeostatic cytokines rather than cognate Ag stimulation 
are the major mechanism involved in self/tumor antigen-specific differentiation of TN 
into effectors and memory cells. Our data suggest that, in the lymphopenic 
environment that is observed post-transplant, pt-Cy-resistant donor TN cells 
generates TSCM both at the polyclonal and Ag–specific level, and that they 
subsequently contribute to immune recovery.  
Despite the molecular mechanisms that are at the basis of long-term memory 
formation have been in part elucidated in the past decade, it is still unclear whether 
the same signals regulate TSCM cell differentiation in humans. The expansion of high 
numbers of TSCM with enhanced multipotency, self-renewal, anti-tumor and long-
term persistence capacity has important practical implications for conditions where 
potent and long-lasting T cell responses are needed, including HSCT and ACT. 
Therefore, in the second part of this work we concentrated our effort in optimizing a 
method to generate high numbers of CD8+ TSCM derived from unprimed TN 
precursors. We showed that curtailed TCR activation induced the generation of 
early-differentiated CD45RA+CD45RO– TSCM cells from TN cells (Figure 15), and 
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that this was associated with a weak upregulation of transcription factors and 
molecules involved in effector differentiation and T cell activation (Figure 18). 
Similar phenotypes could be observed by using beads other than Miltenyi beads, 
i.e., Dynabeads (Thermo Fisher, data not shown), that are currently used in clinic 
trials for the expansion of T cells in ACT. 
Previous reports demonstrated that TN stimulated with a high bead:cell ratio (i.e. 
3:1) induced an unexpected double positive CD45RO+CD45RA+ phenotype that is 
rarely found in vivo37. It has been previously demonstrated that the strength of TCR 
signaling can influence effector and memory formation134. Therefore, we 
hypothesized that lowering the amount of signals to be delivered by beads to T cells 
could influence TSCM cell formation. Indeed, by using a 1:2 aCD3/28 bead:cell ratio, 
we could generate TSCM cells with a naturally-occurring CD45RO–CD45RA+ 
phenotype. To better define the role of TCR stimulation in this regard, we delivered 
differential signals via CD3 and CD28 by titrating antibodies capable to activate 
these signalling molecules and we found a role for CD3, but not for CD28 in the 
generation of the CD45RO+CD45RA– TSCM phenotype (Figure 19). Thus, the 
strength of TCR signal via CD3 can influence the type of progeny derived from TN 
cells, while costimulation plays no role in this regard, at least in this in vitro model. 
The generated TSCM showed similar features to naturally-occuring TSCM in terms of 
proliferation, self-renewal capabilities, multipotent abilities and cytokine profile in 
response to Ag-specific and polyclonal stimulation (Figures 15, 16 and 19). 
Interestingly, we could not identify differences in the quality of the TSCM response 
following priming with low and high affinity MART-1 peptides, EAA and ELA 
respectively. EAA binds TCR with a decreased strength compared to his heterolitic 
form ELA, and resulted in lower total number of MART-1  specific CD8+ T cells. EAA 
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selects those TCRs with the highest avidity that is in turn associated with increased 
anti-tumor activity135. For this reason, it has been supposed that vaccines delivering 
the EAA peptide would induce a better response compared to ELA containing 
vaccines135. Vaccination regimens with ELA rather than EAA, coupled with CpG and 
Montanide in melanoma patients, resulted in early generation (< 3 month) of MART-
1 specific TSCM. These cells showed long term persistence capabilities135. 
Differently, studies conducted in rhesus macaques infected with simian 
immunodeficiency virus (SIV), showed that Ag-specific TSCM appeared much earlier, 
i.e., 7 days after infection24. These cells expanded clonally and coincidentally with 
the formation of TEff  cells, but showed higher expression of self-renewal and 
persistence molecules such as BCL2, MCL1, LEF1 and lower expression of 
activation (HLA-DR) and proliferation (Ki-67) markers compared to TEff, thereby 
suggesting that they have higher capacity to develop into stable memory cells24. 
Overall, this could reflect limited TCR stimulation occurring in vivo. 
iTSCM also showed lower mitochondrial content compared to iTEff. (Figure 18) In 
line with these results, a previous report analysed the mitochondrial content of 
sorted CD8+ T cell subsets by transmission microscopy and observed that 
mitochondrial content increases in memory subsets (TCM and TEM) compared to TN 
cells126. In contrast, Van de Windt wt al., showed that T cells activated in the 
presence of IL-2  for 3 days and switched in IL-15 for 2 additional days, an approach 
to mimic the generation of memory T cells in vitro, had an increased mitochondrial 
content compared to those kept in IL-2 (and thus resembling effecor cells)136. 
Differences in protocols used to differentiate memory and effector T cells could 
explain these contrasting results. When generating TSCM cells from TN, we avoid 
exposure to IL-2 which could prime T cells for effector differentiation and apoptosis. 
88 
 
 
The general feeling among laboratories generating cells for ACT is that IL-2 should 
be avoided in order to limit excessive differentiation137 and loss of the anti-tumor 
capacity97.  
Inhibition of effector differentiation of TN precursors has been achieved in multiple 
ways, such as pharmacological intervention, cytokine cocktails and genetic 
manipulation138. More recently it has been demonstrated that TSCM formation can be 
induced by the use of bromodomain and extra-terminal motif (BET) inhibitors, which 
in turn limit BATF expression111. Of note, BATF is part of a multiprotein DNA-binding 
complex comprising Jun and IRF4 or IRF8 and is involved in the formation of 
effector T cells139. Our experiments suggest  that a mild IRF4 and IRF8 upregulation 
are necessary for the activation of TN cells but dispensable of TSCM formation.  
In conclusion, we show that adoptively-transferred TN cells generate TSCM cells in 
the context of h-HSCT, and that these cells play a non-redundant role in subsequent 
T cell reconstitution. Given the relative polyclonality of these TN-derived TSCM, 
adoptive cell transfer of such cells generated in the laboratory could be conceived. 
We further show that TSCM cells can be generated from TN precursors by curtailed 
TCR stimulation during priming. Current effort in the laboratory is devoted to identify 
further downstream molecular signals that can be further exploited in the context of 
TSCM differentiation and ACT. 
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